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Abstract 
 
 This report details the work performed over a period of five years in an NIJ-funded 
project intended primarily to develop a practical means for accessing the large reserve of genetic 
variation in the ~15,000 bp mtDNA coding region, as a means for augmenting the forensic 
discrimination provided by sequencing the hypervariable (HV) regions of the mtDNA control 
region.  Our approach was to focus on the relatively small number of particularly common types 
present in US Caucasian, African American, and Hispanic populations, where the problem of 
limited discrimination is concentrated in practice.  We sequenced 506 entire mtDNA genomes 
corresponding to 56 common HV types present at 0.5% or more in the respective populations.  
Full genome sequencing resolved the 56 HV types into 423 haplotypes, and permitted the 
identification of 123 SNP sites suitable for practical assay development.  Selection criteria for 
target SNPs included that they be present in multiple individuals, not be redundant with variation 
in the HV regions, and that they not occur at positions that affect either amino acid sequence or 
changes in structural RNA genes.  Selected discriminatory SNPs were organized into panels that 
are specific for particular common HV types, or their near relatives.  The intent was for a 
forensic scientist, encountering a common HV type, to be able to turn to one or two multiplex 
assays that represent the best chance for detecting additional discriminatory variation for the HV 
type in question.  This was demonstrated to be a particularly effective strategy based on the 
observed distribution of variation in the mtDNA coding region.  For Caucasian common HV 
types, eight multiplex allele-specific primer extension (ASPE) assays were designed, optimized, 
and tested.  These proved to be highly suitable with regard to characteristics important for 
forensic mtDNA testing.  Developmental validation for sensitivity, mixture detection, and 
degraded samples was completed for seven of the eight panels (one still in development).  One 
multiplex has been applied in numerous case investigations, establishing a clear practical utility.  
Population databases were established for the completed multiplexes.  Additional work on this 
project included generation of new control region databases, including four regional Hispanic 
population samples that were significantly differentiated at the haplogroup and haplotype level.  
Also developed, in a collaborative project, was a multiplex ASPE SNP assay for haplogroup 
assignment among mtDNAs of W. European origin.
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Structure of This Report: 
 
 In order to maximize the efficiency of reporting the large body of data and analysis that 
has resulted from this project, we will convey the information in three main sections:   
1.  An Executive Summary that can serve as a stand-alone overview of the project, its methods, 
and findings;  the summary points the reader to more detailed information/discussion in one of 
the other two following sections. 
2)  An Experimental Details and Main Findings section that provides 
a)  an abbreviated review of background, results, protocols, and discussion relating to 
portions of this project that have already been published, with appropriate reference to the 
published work; 
b)  a detailed presentation of results, protocols, and discussion that has not been 
previously published; 
3)  Several appendices containing technical information. 
 
Note on Ethnic/Racial Categories:   Following a convention that is common in forensics in the 
United States, this report will refer to the following ethnic/racial categories:  US Caucasian, 
African American, and Hispanic.  These essentially reflect categories of self-identification when 
individuals are given a small number of pre-set choices for ethnic/racial association (on forms, or 
in the national census, etc…).  It is not the case that any of these categories behave as distinct 
biological populations, or can be clearly defined in genetic terms.  All three are of heterogeneous 
origin and experience significant degrees of admixture, both historical and present-day.  It may 
be the use of these terms in forensics ought to be revised, but this issue is beyond the scope of 
this project/report, and the standard usage is retained solely for convenience, and to relate to 
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current practices.  Nevertheless, the three categories as referred to in this report represent 
significantly different distributions of mtDNA sequences and the project was usefully structured 
around separate studies relating to each; overlap between the categories is evident in the results 
of this study and will be noted. 
 
 
Executive Summary: 
 
 This is the final report of a two stage, five-year grant project funded by the National 
Institute of Justice (award number:  2000-IJ-CX-K010).  The first stage of this award, spanning 
9/30/2000 to 9/30/2002 was entitled:  Homogeneous Fluorescent PCR Assays for Forensically-
Informative Sites over the Entire mtDNA Genome:  Increasing the Power of Discrimination, 
Ease, and Speed of Forensic mtDNA Testing.  A supplementary award permitted continuation of 
this work from 10/1/2002 to 10/1/2005 with the same award number, but a revised title:  
Mitochondrial DNA Genome Sequencing and SNP Assay Development for Increased Power of 
Discrimination.  The latter will be chosen for the overall project title in this report.  A no-cost 
extension of the grant activity period has been awarded till 12/31/05, to permit completion of 
some work and reporting of results. 
 
Background and Introduction: 
 
 Forensic testing of mtDNA sequence variation has become well established to assist in 
identification casework, primarily in criminalistic and missing persons applications (Holland and 
Parsons, 1999).  MtDNA typing is performed mostly under two circumstances:  1) when 
degradation of DNA or sample type makes recovery of nuclear DNA difficult or impossible, and 
2) when comparison to matrilineal relatives is desired.  Critically important features of mtDNA 
that underlie its application are the following:  1)  it is present in high copy number per cell (on 
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the order of 1000 depending on cell type), 2)  it is maternally inherited, and 3)  is does not 
recombine.  In its current practice, mtDNA typing usually targets complete sequence 
determination of 610 bp of the control region (or D-Loop), from two portions referred to as 
hypervariable region I (HV1, 16024-16365) and hypervariable region II (HV2, 73-340).  Results 
from this sequencing are reported as a list of nucleotide positions at which there are differences 
from a standard reference sequence referred to as the “Anderson” sequence, or more commonly 
now the rCRS (the revised Cambridge reference sequence, Anderson et al. 1989; Andrews et al., 
1999).  [In this report, HV-type will be used as shorthand to mean a particular haplotype with 
defined by the full sequence of HV1 and HV2.] 
 Because mtDNA is a non-recombining locus, sequence polymorphisms must be treated as 
wholly linked within the same molecule.  Therefore, in order to determine the evidentiary 
significance of an mtDNA sequence match, one cannot consider the frequency of individual 
polymorphisms, but rather the frequency with which the entire haplotype occurs within relevant 
populations.  This requires reference to large population databases of mtDNA sequences.  Both 
forensic and academic studies have generated vast amounts of mtDNA control region sequence 
variation from populations worldwide, although only a small proportion of this is available for 
forensic applications due to the requirement for a searchable compilation of uniform sequence 
ranges and consistent quality control criteria.  The basic structure of mtDNA variation in all 
populations is such that a majority of HV-types are rare, with a small number of more common 
types.  The frequency distribution of any population will reflect its own history regarding age, 
migration patterns, founder effect, and population expansion.   
 Figure 1 illustrates the frequency distribution of HV-types in the US Caucasian 
population.  The most common HV-type is present in > 7% of the population while ~50% of the 
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population is “unique in the database” (Fig 1).  While most sequences are rare and of 
correspondingly high evidentiary value, only a small portion of HV-types are present at ~0.5% or 
greater in the population.   In US Caucasians, about 20% of individuals have an HV-type that has 
a frequency of 0.5% or more of the population, and it is in these relatively common sequences 
where mtDNA manifests its greatest limitation:  a low power of forensic discrimination.  A 
similar skewed mtDNA frequency distribution is characteristic of African American and US 
Hispanic populations, as well. 
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Figure 1:  Frequency Distribution of mtDNA Types in a US Caucasian Database.  
Frequencies based on FBI database of 1219 Caucasian individuals.   
 
 
 
 
 
 The practical consequence of the mtDNA frequency distribution listed above is that about 
20% of the cases that are encountered will involve an HV-type with decidedly limited 
evidentiary value in comparison to the rarer types (for most of these, the evidentiary significance 
is limited by the size of the database).  This has its greatest effect in cases involving multiple 
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sequence comparisons, involving multiple individuals;  extreme examples are mass fatality 
incidents, or searches of missing person’s databases.  Under those conditions it is not 
uncommon, and in large cases it is assured, that reference samples for unrelated missing 
individuals will be indistinguishable in HV-type, therefore negating any ability to 
unambiguously associate a questioned sample with the proper family reference.  This is 
complicated further by the standard requirement that at least two mtDNA sequence differences 
need to be present to constitute a practical exclusion.  What is needed is some means for further 
distinguishing between individuals who match in HV-type.   
 Sequence variation in mtDNA is concentrated in the non-coding control region, and 
especially the HV regions, with an evolutionary nucleotide substitution rate in the control region 
approximately ten-fold higher than in the coding region.  This makes the HV regions the obvious 
first choice for seeking mtDNA variation, but Figure 2 shows a scale map of the mtDNA genome 
that makes it clear that even with a 10-fold lower rate of variation, a majority of the sequence 
variation in mtDNA occurs in the coding region (as there is ~15 times more coding region).  
Given that regions outside of HV1/HV2 also contain large amounts of variation, our logic at the 
outset of this project was that by extending typing beyond HV/HV2 it ought to be possible to 
substantially alleviate the low power of discrimination of mtDNA testing.  However, it was also 
anticipated that sites that provide additional discrimination, in relation to HV1/HV2 sequences, 
would be relatively rare, widely scattered, and dependent on the sequence background reflecting 
the history of particular mtDNA haplogroups.  Unfortunately, the complete linkage of mutations 
over the mtDNA genome results in the fact that most randomly encountered coding region 
mutations are likely to be redundant, in terms of forensic discrimination, either with each other, 
or with variation already accessed by sequencing HV1/HV2.  Because of the lower evolutionary 
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rate in the coding region, most mutational variants in the coding region are older than those in 
the D-loop, with the anticipated results that fast evolving D-loop mutations tend to discriminate 
within coding region lineage markers, rather than vice versa.  Based on these considerations, 
which in the end proved to be correct, it was decided to identify additional discriminatory 
information by a brute force approach:  for the most common HV-types in a population, multiple 
individuals matching that type would be sequenced for the entire mtDNA genome (mtGenome) 
to identify the specific single nucleotide polymorphisms (SNPs) that provide maximal increased 
discrimination.   
This undertaking, applied separately to US Caucasian, African American, and Hispanic 
populations represents the bulk of the work performed in this project, together with the 
development of appropriate SNP assays that permit recovery of the discriminatory markers from 
real world forensic samples.  Associated with these overarching goals were a number of 
component subprojects, and related investigations which are summarized below. 
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Figure 2.  Physical Map of the mtDNA Genome  
From www.mitomap.org.  Colored regions indicate protein-coding, ribosomal RNA, or tRNA genes. 
 
 
 
 
 
Overview of Specific Goals: 
Specific stated goals of this project, over its five-year duration, were the following:  
1)  Sequence the entire mtDNA genome of multiple individuals corresponding to the most 
common mtDNA types (within hypervariable regions I and II) in the US Caucasian, African 
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American, and US Hispanic populations, and identify nucleotide sites that provide increased 
forensic discrimination among these common types. 
2)  Create new databases of mtDNA control region sequences for African-American and U.S. 
Hispanic individuals so that physical samples corresponding to common HV1/HV2 types would 
be available for mtGenome sequencing. 
3)  Evaluate the potential for forensically significant regional variation in mtDNA distribution 
among the populations studied under goal 2) above. 
4)  Develop SNP assays for selected informative sites that perform suitably for forensic mtDNA 
applications and establish developmental validation with relation to a)  sensitivity, b)  mixture 
and heteroplasmy characterization, and c)  performance on degraded DNA.    
5)  Establish population databases of SNP loci on samples for which other primary forensic 
markers have also been typed (mtDNA control region sequences, autosomal STRs, Y-STRs, and 
Y-SNPs). 
6)  Develop multiplex coding region SNP assays for determining world mtDNA haplogroup 
attribution of mtDNAs from unknown individuals.   
 
Summary of Progress on Goals: 
 
 
1)  Entire mtDNA Genome Sequencing and identification of Discriminatory SNPs. 
 In order to meet the high throughput sequencing goals of this project, a system of 
automated instrumentation was developed together with informatic tools for automated data 
transfer and analysis.  Robotic instruments were employed in the following process stages, 
processed in 96-well plates: blood or buccal swab punching;  DNA extraction;  PCR 
amplification;  post-PCR clean-up; dideoxy-terminator cycle sequencing reaction set up; and 
11 
This document is a research report submitted to the U.S. Department of Justice. This report has not 
been published by the Department. Opinions or points of view expressed are those of the author(s) 
and do not necessarily reflect the official position or policies of the U.S. Department of Justice.
post-sequencing clean-up.  Automated fluorescent sequencing was performed on either ABI 377 
polyacrylamide gel instruments (early on in the project), or the with the multi-capillary array 
instruments, the ABI 3100 or ABI 3730.  Sequence data analysis was performed using the 
assembly program Sequencher (GeneCodes Corporation, Ann Arbor, MI), and unambiguous 
consensus sequences were finalized through a information management system that eliminated 
manual data transcription, facilitated efficient review and confirmatory checking, and exported 
data into a final locked database from which additional analysis could be performed without fear 
of corruption of the original data. 
 For the project, the following numbers of mtGenomes were sequenced:  241 Caucasian 
individuals, representing 18 common HV-types;  140 African American individuals, representing 
20 common HV-types; and 125 Hispanic individuals representing 18 common HV-types.  In all 
three groups, large numbers of candidate SNPs were discovered that, in general, provided a large 
degree of additional forensic resolution in comparison to the HV-types alone.  The data were 
scrutinized for the identification of SNPs useful for practical forensic assays using the following 
criteria:  i)  the SNP variants should occur in more than a single individual, ii) the SNPs should 
not be redundant in providing discrimination, and iii) the SNPs should occur at either non-coding 
positions, or the variants should involve synonymous substitutions within protein-coding genes. 
Details of the increased forensic discrimination provided by both the entire mtGenome sequences 
and panels of select SNP sites are presented below for all three ethnic groups, and for US 
Caucasians were published in Coble et al. (2004), and discussed in Coble (2004).  There were  
506 mtGenomes sequenced for this study, representing only 56 different HV-types; when the 
complete mtGenome was taken into account, these resolved to 423 distinct mtDNA sequences.  
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377 of the sequences were unique, so that 74% of the original 506 samples were found to be 
distinct from all other mtDNA types upon full sequence analysis. 
 
2)  mtDNA Control Region Databases 
 In order to accomplish this study, it was necessary to have DNA samples matching 
common HV-types to sequence for the mtGenome.  The common HV-types to target were 
identified through pairwise comparisons of the SWGDAM mtDNA population database and 
internal AFDIL databases.  AFDIL contributed a majority of the Caucasian sequences in the 
SWGDAM database, and for Caucasians was able to identify a suitable number of in-house 
samples matching the common types for completion of the study.  Use of AFDIL samples for 
this study was approved by the Armed Forces Institute of Pathology Institutional Review Board, 
and all samples were rigorously anonymized to avoid any genetic information identifiable to a 
named individual.  For the Hispanic and African American groups some additional samples 
matching common types had to be obtained.  For this purpose, new control region databases 
were established with samples obtained from collaborators.  Data collection, review, and 
archiving was achieved using the same robust, automated system as was developed for the 
mtGenome sequencing.  The new databases were:  249 African Americans, and four regional 
Hispanic samples:  Florida (n=96), Texas (n=200), Midwest (n=128) and New York (n=151).  
The African American samples and the Midwest Hispanics were from the NIST population 
collection for which many other forensic markers have also been typed.  The new mtDNA 
control region population databases have been submitted to EMPOP (www.empop.org), a new 
online searchable international mtDNA population database.  Pending final crosschecking of data 
between EMPOP and AFDIL, the data will be submitted to GenBank, donated to the SWGDAM 
database, and prepared for publication. 
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3)  Regional Substructure in US mtDNA Population Databases 
 Few studies have investigated the level of heterogeneity existing within regional 
population subsamples from the major “ethnic” groups as traditionally considered in forensic 
databases.  “Hispanics” are poorly defined, and can represent individuals of Native American, 
Caribbean, Central American, South American, and European heritage, with mtDNA 
contributions of Native American, European, and African origin.  We obtained four regionally 
distinct Hispanic population samples for the control region databasing portion of this grant, 
permitting an initial investigation into the degree to which regional Hispanic samples may differ 
from one another.  The results were rather striking, but in line with expectation:  the different 
samples reflect divergent mtDNA distributions, reflecting a different history of migration and 
admixture within each of the samples.  Figure 3 shows components of each population sample, 
broken down by categorization of the mtDNA types into continental origin, by virtue of 
identifiable sequence motifs associated with mtDNA haplogroups.  
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Figure 3.  Major haplogroup affiliations for regional Hispanic population samples. 
Database sizes were Midwest (128), New York (151), Texas (200), and Florida (96). 
 
 
 
 
 
Each of the samples reflect differential composition of haplogroups of  Native American, 
European, and African origin that seem consistent, broadly, with trends one might expect.  For 
example, the New York population sample is comprised of more than 40% African haplotypes 
probably reflecting a stronger Afro-Caribbean contribution, while the Texas sample shows 
almost no African mtDNA types, with a strong predominance of Native American mtDNAs, 
probably reflecting a primarily Mexican/Central American contribution.  
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4) SNP Assays Suitable for Forensic Applications 
 
 Having identified many sites over the entire mtGenome capable of providing additional 
forensic discrimination, the next project goal was to develop an assay system and conceptual 
approach allowing the information to be accessed in useful manner, bearing in mind the real 
world constraints of forensic casework samples.  Since mtDNA testing is normally dictated by 
the advanced degradation of the sample, with low amounts of fragmented DNA, there is a clear 
requirement that the testing method be highly sensitive and use short amplicons.  Additionally, a 
multiplex amplification approach is highly desirable given the typical limitations of extract 
volume from degraded samples; and, because of the prospects for heteroplasmy and/or mixture, 
the assay must be able to quantitatively represent these conditions to some practical extent.   
The distribution of discriminatory sites, and their specificity to particular HV-types, 
indicated that the best approach for a typing assay would be to target particular strategic SNPs, 
rather than sequence broad sections of the mtDNA coding region  (considerations relating to this 
are presented in more detail in Coble et al., 2005).  Moreover, we were guided throughout by a 
desire to usefully complement the current state of the art of mtDNA testing (sequence analysis in 
HV1-HV2, or sometimes in adjacent areas of the control region), rather than to redesign mtDNA 
typing in its entirety (as would be conceptually possible using a dense SNP typing approach, for 
example).  The intended goal was to identify a suitable, off-the-shelf SNP typing platform that 
would be relatively easily accessible to wide variety of practitioners, and to adapt it to a number 
of assays that practitioners could turn to in particular circumstances where common HV-types 
are encountered to maximize the chance for increased discrimination with just one or a few 
additional multiplex amplifications. 
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 The initial focus for a readily available SNP assay platform was on the TaqMan® 
fluorogenic system by ABI.  This system was investigated in collaboration with Harrald 
Niederstätter and Walther Parson (University of Innsbruck) regarding sensitivity and mixture 
detection, and found to be quite suitable (results of these analyses were published in 
Niederstätter et al., 2005).  However, the system was not amenable to multiplexing, and the data 
analysis and manipulation was found to be cumbersome.  In collaboration with Peter Vallone 
(NIST) we began working with the SNaPShot™ allele specific primer extension (ASPE) assay, 
and this became the platform for further development. 
 We designed, optimized, and performed developmental validation of the ASPE assay for 
eight multiplex panels that target common HV types in Europeans.  Each multiplex was tested 
for sensitivity, mixture/heteroplasmy detection, and use on degraded skeletal remains extracts.  
The details of the work for Multiplex “A,” targeting the most common Caucasian HV type were 
published in Vallone et al. (2004).  Details of the stages of design, optimization, and testing for 
the other multiplex panels, are included in Experimental Details and Main Findings below.  The 
SNP assay panels are intended to be used when needed for particular HV types or their near 
relatives, when encountered in casework.  Because of variation in the number of discriminatory 
SNPs identified for particular HV types, and some overlap in SNPs that discriminate within 
multiple common HV types, some HV types are targeted by more than one SNP panel, and some 
SNP panels are designed for more than one HV type (details below).  Optimization for one of the 
Caucasian panels, D, has not been completed as of the expiration of the grant period, but will be 
completed and included in future publications.  Following the model described above for 
Caucasian HV types, similar panels have been devised for common African American and 
Hispanic HV types, although SNP assays have not been designed or tested.   
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 While conceptually straightforward, and—once optimized—simple in practice, multiplex 
SNaPShot ASPE assay development for practical forensic use can be problematic and lengthy.  
While it is comparatively simple to devise a “quick and dirty” ASPE assay where an investigator 
can infer results while ignoring many and various artifact peaks, bringing the assay to a stage 
where standardized interpretation guidelines typical of forensic testing can be applied is 
substantially more challenging. There are a variety of reasons for this, such as primer interactions 
and PCR competitive effects that are only evident in later stages in the development process.  
The single largest difficulty in our experience was in obtaining high quality preparations of the 
many, sometimes quite large, primers used in the assay.  The assay is rather prone to artifact due 
to minor problems or variation in primer synthesis.  Sometimes the causes are identifiable (minor 
components of incompletely synthesized extension primers;  inaccurate quantitation by 
manufacturer), sometimes not (unusual artifact peaks or blobs resulting from a new lot of 
primer).   
The ASPE assays required additional minor modifications (increasing Taq and 
amplification volume) to become suitable for typing of degraded sample extracts.  However, 
once optimized, the assays were highly sensitive and performed well with even highly degraded 
samples, as the amplicon sizes are small and the detection platform inherently sensitive.  AFDIL 
has used Multiplex A successfully in quite a few investigatory cases where additional 
discrimination was required.  The utility in these cases was to exclude multiple matching 
reference families, or to confirm association among multiple elements.  The utility of these 
assays, and of the approach of selectively augmenting forensic resolution in a directed manner 
with specific SNP panels, has therefore been clearly established. 
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5)  SNP Panel Population Databases 
 
 For seven of the eight Caucasian multiplex panels, databasing was performed on a 
random population sample of 284 US Caucasian individuals.  These samples were from the 
population reference collection held by NIST, for which a large number of other forensic loci 
have been typed (http://www.cstl.nist.gov/div831/strbase/NISTpop.htm).  The purpose of this 
databasing was to assess the effect of the various Caucasian ASPE assay panels on random 
population samples (see results below in Experimental Details and Main Findings).  These 
panels do not provide particularly powerful stand-alone resolution, as was expected since they 
were not designed for this purpose.  For example, multiplex A by itself resolves 281 individuals 
into only 17 different types.  However, when combined with HV sequence data, as intended, our 
SNP database results indicate a significant utility for the assays (detailed information for all the 
panels is presented in Experimental Details and Main Findings, below).  46 individuals in the 
NIST Caucasian database match either the most common Caucasian type (H:1, present in 6% of 
this database), or differ from it by a single base, with the 46 individuals representing 10 different 
HV types.  As designed, one might turn to multiplex A for additional resolution for any of these, 
which would resolving the 10 HV types into 22 HV/SNP types, 14 of which are now unique in 
the database.  Four of the H:1 sequences would be resolved to “unique in the database” (i.e. > ~ 
0.4%), for a ~15-fold increase in evidentiary significance.  
 
6)  SNP Assays for Haplogroup Attribution  
 One goal of the second, supplementary portion of this project was the development of 
SNP panels based on the mtDNA coding region that would permit haplogroups to be 
unambiguously assigned.  Work was performed on this in collaboration with Anita Brandstätter 
and Walther Parson (University of Innsbruck), resulting in an ASPE assay for 16 SNPs that 
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permit the classification of major W. European haplogroups and sub-haplogroups (Brandstätter, 
et al. [2003] and [2004]).  As our project progressed, however, no further effort was applied to 
this goal for two reasons:  1)  greater than anticipated effort in SNP assay development for the 
discriminatory panels, and 2) a number of other groups became active with similar projects, such 
as the SNPforID Consortium (www.snpforid.org, see also, e.g., Grignani et al. [2005]), and there 
seemed little benefit in competing or performing redundant work. 
 
Executive Summary, Conclusions and Future Directions 
 
 This project has resulted in the development of a series of multiplex SNP assays that 
forensic scientists can use for significantly enhancing the discrimination when common 
Caucasian HV types are encountered in casework.  It is in such cases that the need for increased 
discrimination will occur most frequently and will be the most pressing.  506 entire mtDNA 
genomes were sequenced for this study, and useful panels of discriminatory SNPs were also 
identified for common HV types with African Americans and Hispanics.  Control region 
databases of four regionally distinct Hispanic samples indicate that there is substantial regional 
differentiation within individuals ascribed to this heterogeneous classification.  This indicates the 
desirability of increasing the sample size and regional representation within US forensic mtDNA 
databases.   
 The data generated from this project will likely be of primary significance as the field 
progresses toward routine utilization of coding region variation in forensic mtDNA testing.  
Maximum utility would be achieved with commercialization of robust SNP typing kits targeting 
the sites we have identified, as well as other sites identified through further characterization.
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Experimental Details and Main Findings 
 
Control Region Sequencing. 
 Partly as a result of the system developed in this project for robotic sequencing of the 
mtGenome, the AFDIL research section has a highly refined system for high throughput control 
region sequencing.  This employs robotic automation in chemistry steps, and an effective 
bioinformatic data management system that facilitates a rapid but robust data review process, and 
preserves data integrity by removing any manual transcription of data.  In the end, data is stored 
in a locked database to prevent corruption and inadvertent over-writing.  Primary sequence 
alignment and editing is performed only a single time by a single scientist, but the resulting 
Sequencher layout and consensus sequence export is independently reviewed at various stages by 
two additional scientists.  One reason this system works so effectively is that the sequence 
coverage was designed to be highly redundant, with a good chance of obtaining full double 
strand coverage even in cases where C-stretch length heteroplasmy is present in HV1 and/or 
HV2 (see figure 4).  This results in larger than necessary reagent costs for “easy” samples, but 
more than pays for itself by reducing effort in the rate limiting step (data analysis is simplified by 
very strong support for base calls), and decreasing the amount of specific re-do reactions which 
are time consuming and error-prone.  When human handling is required, as in blood stain 
punching to plates using a Wallac hole puncher (figure 5 shows the robotic processing steps in 
the CR sequencing process), or particular wells of plates are accessed for re-do’s, three scientists 
are involved for a redundant check that no errors are introduced.  Amplification, cycle 
sequencing reaction conditions, and clean-up were as described in the section below on Whole 
Genome Sequencing.  Amplification and sequencing primer sequences are listed in Appendix I. 
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The following steps outline the data analysis and review of  CR sequence data:   1)  
Scientist 1 performs alignment in Sequencher (GeneCodes, Ann Arbor, MI, version 4.1.4Fb19), 
checking for unambiguous double strand coverage, and generating a list of differences 
(“polymorphisms” by colloquial reference) from the Cambridge Reference Sequence (CRS;  
Andrews, 1992);  2)  Scientist 2 reviews strand coverage, independently deduces the 
polymorphisms of the consensus sequence, and generates a text file of the polymorphisms;  3)  
Scientist 1 exports the text file to the database and compares this to the list he/she independently 
generated; once confirmed, Scientist 1 clicks the “Initial Review” button on the database GUI;  
4) Scientist 3 confirms the data as entered into the database with reference to the origin 
polymorphism lists, and elevates the status to “Final Review” whereby the sequence becomes 
locked in the database and can only be modified by an administrator. 
Our system of data analysis has been validated through complete independent reanalysis 
of multiple databases, performed by the University of Innsbruck, Institute of Legal Medicine, 
when our samples were submitted for the EMPOP database (www.empop.org). 100% 
concordance in results were obtained.   Additional quality control analyses using phylogenetic 
methods have been applied to one of our databases, published in Brandstätter et al. (2004).  The 
rigor we have applied to ensuring the high quality or our final mtDNA sequence data is 
motivated by the huge amount of attention that mtDNA database errors have received in recent 
high profile publications (e.g. Bandelt et al., 2002, 2004a, 2004b). 
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Figure 4. Control Region Sequencing Strategy. 
Sequencing primer placement strategy for full double stranded confirmation of CR sequence even when 
C-stretch length heteroplasmy is present (HV1 and HV2 C-stretches shown).  Some primers are used 
twice (rep.1 and rep.2). 
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Plate Flow Chart – Control Region Sequencing
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Figure 5.  Control Region Sequencing Overview 
Overview of robotic laboratory processing for high throughput CR sequencing. 
 
 
 
 
Regional Substructure in US mtDNA Population Databases 
 
 Figure 3 of the Executive Summary (above) depicts the results of four regional 
“Hispanic” population samples, at the level of haplogroups ascribed to continental origin.  It is 
clear at a glance that these samples do not reflect subsets of a single homogeneous population, 
due to pronounced deviation in representation at the haplogroup level. This suggests that the 
issue of regional variation should be addressed with further sampling amongst various groups 
that are currently maintained as single population designations.  However, the practical 
significance of such subdivision in forensic applications is something that should be examined 
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carefully.  Given large enough sample sizes, we can anticipate with certainty that significant 
differentiation will be the rule among any regional subsamples, but the practical effect may be 
low when examined on the haplotype (rather than haplogroup) level.  As an extreme example for 
the purposes of discussion, if each of the regional Hispanic samples were comprised of 
sequences that were unique within and between the databases, the fact that these are 
“significantly differentiated subpopulations” would by itself have no effect on forensic reporting.  
However, it does appear that there would be practical difficulties associated with simply 
combining these separate databases together.  For example, the most common type in the Texas 
Hispanic dataset is found in 8/200 (4%) of that database, but is not present at all in either the 
New York or Florida Hispanic databases.  Applying confidence limits to reporting these database 
comparisons (following Holland and Parsons [1999]), for the most common Texas Hispanic 
sequence one would report an 95% upper bound for the Texas sample of 4.4%, while the upper 
bound value on the four databases pooled together (10/575) would be reported as 2.5%.  It could 
be debated whether these two values would be significantly different from one another with 
respect to any meaningful effect on a juror’s consideration. However, this does not really address 
the larger question:  when, and under what criteria should databases be pooled together or 
retained as distinct? 
It is beyond the scope and purpose of this report to deal with these issues in depth, 
although a more detailed analysis is planned for a future publication.  Resolution of these issues 
will likely require both dialog among practitioners and population geneticists, as well as a great 
deal more data to frame the question.   
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Whole Genome Sequencing 
 
Pairwise Comparisons and Samples. 
 
Note on HV type naming for this project:  HV types were given names indicating their major 
haplogroup (and in some cases, subhaplogroup) of origin, followed by a number distinguishing 
that type from others of the same haplogroup.  The haplogroup designation and sequential 
number (e.g. L3e:1) are separated by a colon in an attempt to avoid confusion with other 
subhaplogroup identifiers. 
 Pairwise comparisons of the relevant SWGDAM mtDNA forensic databases were 
performed to identify the common HV types for each of the Caucasian, African-American, and 
Hispanic populations.  For each pairwise comparison, the regions were restricted to positions 
16024-16365 and 73-340.  Insertions at positions 16183 and 309 were ignored.  HV types that 
occurred at a frequency of greater than 0.5% in each population were selected as the target 
“common” HV-types.  With reference to diagnostic polymorphisms associated with continental 
origin, in Hispanics, 13 of the common HV types were of Native American origin, four were of 
European origin, and two were of African origin.  The common types within African Americans 
were all of African continental origin, and the common types within US Caucasians were all of 
European origin. 
Samples from each of the common HV-types for whole genome sequencing were 
obtained from one of three sources: 1) AFDIL family reference samples, 2) CR population 
databasing samples, and 3)  samples provided by the FBI from the SWGDAM database.  The 
AFDIL family reference databases were searched for samples matching the common HV-types.  
When samples were identified, the bloodstain cards were obtained and the samples anonymized 
prior to processing.  The control region population databases generated from the NIST African-
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American and Hispanic samples, as well as Hispanic samples from other sources, were combed 
for samples that matched the common HV-types.  Thus the number of samples sequenced  for 
each of the common HV-types was limited by sample availability from the family reference and 
CR population databases.  Tables 1-3 list the HV sequences, population frequency (within the 
SWGDAM database for each ethnic group), and number of individuals sequenced for the entire 
mtGenome.   
 
 
 
HVI/HVII 
Types 
% of 
Population 
Matching 
HVI/HVII 
Type 
# of 
Samples 
Sequenced 
HV-type Defining Polymorphisms 
H:1 7.92% 31 CRS 
H:2 2.05% 25 152 C 
H:3 1.03% 11 16129 A 
H:4 0.54% 8 16263 C 
H:5 1.03% 12 16304 C 
H:6 0.91% 11 73 G 
H:7 0.66% 7 73 G   16162 G   16209 C    
J:1 1.21% 15 73 G  185 A  228 A  295 T   16069 T  16126 C   
J:2 0.66% 8 73 G  228 A  295 T   16069 T  16126 C  
J:3 0.79% 13 73 G  185 A  188G  228 A  295 T   16069 T  16126 C   
J:4 0.36% 8 73 G  242 T  295 T   16069 T  16126 C  16145 A  16172 C  16222 T  16261 T   
T:1 1.33% 21 73 G   16126 C  16294 T  16296 T  16304 C   
T:2 0.60% 10 73 G  152 C  195 C   16126 C  16163 G  16186 T  16189 C  16294 T   
T:3 0.66% 8 73 G   16126 C  16294 T  16296 T   
V:1 1.21% 25 16298 C 
K:1 1.09% 14  73 G  146 C  152 C   16224 C  16311 C  
K:2 0.60% 7 73 G    16093 C  16224 C  16311 C   
K:3 0.60% 7 73 G  16224 C  16311 C   
  23.25% 241   
Table 1. Common US Caucasian HV-types sequenced for the entire mtDNA genome.  
Bottom row lists the total number of common HV types, the cumulative percentage of the population 
these types represent, and the total number of mtGenomes sequenced. 
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 HV-types 
% of 
Population 
Matching 
HVI/HVII 
Type 
# of 
Samples 
Sequenced 
HV-type Defining Polymorphisms 
A2:1 3.57% 15 73G, 146C, 153G, 235G, 16111T, 16223T, 16290T, 16319A, 16362C 
A2:2 1.35% 7 73G, 146C, 153G, 235G, 16111T, 16129A, 16223T, 16290T, 16319A, 16362C 
A2:3 1.35% 15 73G, 146C, 153G, 235G, 16223T, 16290T, 16319A, 16362C 
A2:4 1.11% 4 73G, 146C, 152C, 153G, 214G, 235G, 16083T, 16111T, 16223T, 16256T, 16290T, 16319A, 16362C 
A2:5 0.56% 1 73G, 146C, 152C, 153G, 235G, 16111T, 16223T, 16290T, 16319A, 16362C 
A2:6 0.56% 5 73G, 146C, 153G, 235G, 16111T, 16223T, 16274A, 16290T, 16319A, 16362C 
B2:1 1.11% 7 73G, 16182C, 16183C, 16189C, 16217C 
B2:2 0.63% 6 73G, 16111T, 16183C, 16189C, 16217C 
C1:1 2.62% 12 73G, 249D, 290D, 291D, 16223T, 16298C, 16325C, 16327T (-263G) 
C1:2 1.74% 13 73G, 249D, 290D, 291D, 16223T, 16298C, 16325C, 16327T 
C1:3 0.63% 3 73G, 249D, 290D, 291D, 16051G, 16188T, 16204A, 16223T, 16325C, 16327T, 16362C 
C1:4 0.56% 2 73G, 143A, 249D, 290D, 291D, 16086C, 16183C, 16189C, 16223T, 16278T, 16298C, 16325C, 16327T 
D1:1 1.98% 11 73G, 16223T, 16325C, 16362C  
U5:1 0.56% 4 73G, 150T, 16189C, 16192T, 16270T, 16320T 
K:4 2.06% 12 73G, 146C, 152C, 207A, 16182C, 16183C, 16189C, 16224C, 16311C 
J:5 0.79% 5 73G, 295T, 16069T, 16126C, 16145A, 16222T, 16261T 
L1b:3 0.63% 2 73G, 152C, 182T, 185T, 195C, 228A, 247A, 16126C, 16187T, 16189C, 16223T, 16264T, 16270T, 16278T, 16293G, 16311C 
L3e:5 0.56% 1 90A, 97A, 106D, 107D, 108D, 109D, 110D, 111D, 150T, 189G, 200G, 16223T, 16327T 
18 22.37% 125   
      
H:1 1.03% 31 rCRS 
19 23.40% 156   
Table 2. Common US Hispanic HV types sequenced for the entire mtDNA genome.   
Bottom row lists the total number of common HV types, the cumulative percentage of the population 
these types represent, and the total number of mtGenomes sequenced.  The  W. European H:1 type was 
one of the common HV types in Hispanics, but no additional sequencing was performed beyond the 31 
individuals listed Table 1 (for Caucasians). 
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 HVI/HVII 
Types 
% of 
Population 
Matching 
HVI/HVII 
Type 
# of 
Samples 
Sequenced 
HV-type Defining Polymorphisms 
L0a:1 0.29% 4 93G, 95C, 185A, 189G, 236C, 247A, 16093C, 16129A, 16148T, 16168T, 16172C, 16187T, 16188G, 16189C, 16223T, 16230G, 16278T, 16293G, 16311C, 16320T 
L0a:2 0.64% 4 93G, 185A, 189G, 200G, 236C, 247A, 16129A, 16148T, 16168T, 16172C, 16187T, 16188G, 16189C, 16223T, 16230G, 16311C, 16320T 
L1b:1 2.22% 14 73G, 152C, 182T, 185T, 189G, 195C, 247A, 16126C, 16187T, 16189C, 16223T, 16264T, 16270T, 16278T, 16293G, 16311C 
L1b:2 1.07% 5 73G, 152C, 182T, 185T, 195C, 247A, 16126C, 16187T, 16189C, 16223T, 16264T, 16270T, 16278T, 16311C 
L2a:1 2.29% 10 73G, 146C, 152C, 195C, 16223T, 16278T, 16294T, 16309G 
L2a:2 0.72% 4 73G, 146C, 152C, 195C, 16189C, 16223T, 16278T, 16294T, 16309G  
L2a:3 0.79% 4 73G, 143A, 146C, 152C, 195C, 16189C, 16192T, 16223T, 16278T, 16294T, 16309G 
L2a:4 0.93% 10 73G, 143A, 146C, 152C, 195C, 16223T, 16278T, 16294T, 16309G 
L2a:5 1.15% 16 73G, 146C, 152C, 195C, 16189C, 16192T, 16223T, 16278T, 16294T, 16309G 
L2a:6 1.15% 10 73G, 146C, 152C, 195C, 16223T, 16278T, 16286T, 16294T, 16309G 
L2b:1 0.93% 8 73G, 150T, 152C, 182T, 195C, 198T, 204C, 16114A, 16129A, 16213A, 16223T, 16278T, 16355T, 16362C 
L2c:1 0.50% 4 73G, 93G, 146C, 150T, 152C, 182T, 195C, 198T, 325T, 16223T, 16264T, 16278T   
L3b:1 0.43% 3 73G, 16124C, 16223T, 16278T, 16311C, 16362C 
L3b:2 1.00% 5 73G, 16124C, 16223T, 16278T, 16362C 
L3e:1 1.22% 12 73G, 150T, 152C, 195C, 16172C, 16183C, 16189C, 16223T, 16320T 
L3e:2 1.22% 8 73G, 150T, 195C, 16223T, 16265T  
L3e:3 0.72% 3 73G, 150T, 195C, 16172C, 16183C, 16189C, 16223T, 16320T   
L3e:4 0.43% 3 73G, 150T, 195C, 16172C, 16189C, 16223T, 16320T  
L3e:6 1.00% 8 73G, 150T, 195C, 198T, 16223T, 16320T  
L3f:1 0.72% 5 73G, 189G, 200G, 16129A, 16209C, 16223T, 16292T, 16295T, 16311C   
20 19.42% 140   
 
Table 3. Common African American HV types sequenced for the entire mtDNA genome.   
Bottom row lists the total number of common HV types, the cumulative percentage of the population 
these types represent, and the total number of mtGenomes sequenced. 
 
 
 
 
 
 
Whole Genome Sequencing 
 
In total, 506 entire mtDNA genomes were sequenced for this project: 241 Caucasian 
individuals, representing 18 common HV-types;  140 African American individuals, representing 
20 common HV-types; and 125 Hispanic individuals representing 18 common HV-types.  These 
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sequences have been submitted to GenBank with the following accession numbers:  Caucasians, 
AY495090-AY495330;  African Americans, DQ304897-DQ30506;  Hispanics, DQ282387-
DQ282511. 
Most samples identified for whole genome analysis were cut from blood cards or 
bloodstains on cloth using a Wallac Hole Puncher and extracted on the Qiagen 9604 robot.  
Three scientists confirmed the identity of each sample and its placement in the 96-well plate.  
Alternatively, extracts were provided to us from NIST.  In this case, the Corbett-CAS 1200 robot 
was used to aliquot these extracts into 96-well plates used for processing.  At this initial 
sampling step, each sample was given a unique whole genome identifier based on the sample’s 
HVI/HVII type, as determined through previous control region sequencing.  After extraction, 
samples were amplified using the Corbett CAS-1200 robot.  Figure 6 depicts the location of the 
individual amplicons used to amplify the entire mtGenome for each sample, seven per 96-well 
plate, and one amplification negative.   
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Figure 6.  Whole Genome Amplification Strategy.   
From a 96-well plate of extracts, seven individuals (and one amplification negative) are each divided into 
twelve amplicons of varying sizes that span the 16569 base pairs of the entire mtDNA genome. 
 
 
 
 
Amplification primer sets were designed to overlap adjacent amplicons in order to 
provide redundant sequence data and prevent amplicon switches (“phantom recombination”) 
between samples (mtGenome sequencing is described in more detail in Coble et al [2004]).  
Amplicons ranged from 824 to 1885 bases in length, with a minimum overlap between adjacent 
amplicons of 94 bases (maximum 330 bases).  Amplification reactions were performed with 3 ul 
of DNA in 50ul reactions containing components listed in Table 4.  Thermal cycling conditions 
were 96oC for 10 minutes, 40 cycles of 94oC for 15 seconds, 56oC for 30 seconds, and 72oC for 1 
minute, followed by 72oC for 7 minutes and a 4oC soak on the GeneAmp PCR System 9700 
(Applied Biosystems).  The presence of PCR product was confirmed on agarose gels, and post-
PCR clean-up was performed using Exo and SAP. 
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Amplification Component Final Concentration (in 50ul 
reaction) 
MgCl2 1.5uM 
Forward and Reverse Primers 0.4uM each primer 
dNTPs 0.2uM 
TaqGold 2.5 units (0.0025uM) 
10x PCR Buffer 1x 
 
 
Table 4:  Amplification Reaction Components and Final Concentrations. 
Amplification components included MgCl2, Primers, dNTPs, TaqGold polymerase, and a PCR buffer. 
 
 
 
 
 
From the amplification plate containing amplicons from seven individuals, cycle 
sequencing plates were set up using the Tecan Genesis BioRobot with 96 sequencing primers 
targeting a single individual per plate;  seven sequencing plates were required per amplification 
plate.  Five to 12 sequencing primers were used per amplicon (Figure 7). This single sequencing 
plate was designed to produce the entire sequence for an individual, but as the project proceeded 
it was determined that full coverage was rarely obtained with the single plate, so a secondary 
sequencing plate was routinely added with additional primers for more robust coverage;  in this 
case a single additional plate was used for all seven individuals on the original amplification 
plate, with 12 additional sequencing reactions per individual (Figure 8).  In total, 108 sequencing 
primers were used per mtGenome, and it normally required a small number of additional 
reactions, set up by hand on a case-to-case basis, to fill in small gaps in the double strand 
coverage.  For a complete list of primers and primer sequences used in the amplification 
reactions, see Appendix II.   
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Figure 7. Whole Genome Sequencing Strategy.   
In the amplification plate, each row contains one individual.  For the sequencing reaction, each individual 
covers one plate.  Amplification product from each of the twelve amplicons, located in the twelve 
columns of the amplification plate, are distributed across the sequencing plate by the Tecan Genesis 
according to the location of their corresponding sequencing primers.  Here, each color represents a 
different amplicon from a single individual. 
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Figure 8:  Additional Whole G Sequencing Plate.   
An eighth sequencing plate was added to the processing of each seven individuals after it was noticed that 
gaps remained in the sequence data when using only 96 sequences.  Twelve additional primers in six 
amplicons were processed per individual, for a total of 84 additional sequencing reactions per seven 
individuals. 
 
 
 
 
 
 
 
Sequencing reactions were performed as 20ul reactions (2ul of amplification product) as 
listed in Table 4.  Thermal cycling conditions were 96oC for 1 minute, 25 cycles of 96oC for 15 
seconds, 50oC for 5 seconds, and 60oC for 2 minutes, followed by a 4oC soak on the GeneAmp 
PCR System 9700 (Applied Biosystems).     
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Sequencing Component Volume (20ul reaction total) 
dH2O 8ul 
10uM Primer 2ul 
Sequencing Buffer 6ul 
Big Dye 1.5ul 
dGTP 0.5ul 
 
Table 4:  Sequencing Reaction Components and Volumes. 
Sequencing reaction components included dH2O, Primer, Sequencing buffer, BigDye (ABI) and dGTP. 
 
 
 
 
For sequencing reaction clean-up, the samples were run through a Performa V3 96-well 
short plate (Edge Biosystems), dried down, and resuspended in 10ul Hi-Di with the aid of the 
Tecan Genesis for sample transfer steps.  The samples were then run on the ABI 3730 Genetic 
Sequencer using a 50-cm capillary for maximum sequence recovery.  Sequences were analyzed 
in Sequencing Analysis 5.1.1.  Sequence alignments were created using Sequencher 4.1.4Fb19.  
Data analysis, review, and archiving followed the process described in the section on Control 
Region Sequencing, above. 
 
 
 
Selection of SNPs from Common HV-type mtDNA Entire Genome Data and SNP Panel 
Development 
 
 
 Following completion of the whole genome sequencing, the sequence data for each 
population was examined to select discriminatory SNPs appropriate for assay development.  An 
excel file containing only the polymorphic positions for each sample was generated for each 
target population (W. European Caucasian, African-American, and US Hispanic).  Each 
population was examined separately to identify potential discriminatory SNPs that met the 
criteria that: 1) Variation was observed in more than one individual in the population.  The 
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observed variation was either intra-type variation (more than one sample within an HV-type 
varied at a particular site) or inter-type variation (the position was polymorphic and showed 
variation in sample from more than one HV-type).  2) Variation was synonymous.  These 
included SNPs in the Control Region outside of HVI/HVII, coding region intergenic spacers, and 
silent mutations in protein coding genes (first and third codon positions).  One exception was 
made to this criterion, for position 3010, mutation at which results in a non-synonymous change 
in the 16S rRNA gene.  3010 is highly polymorphic in several Caucasian HV-types, and 
mutation at this position is not associated with any known medical disorder.   Once the SNPs 
with potential for assay development were identified for each population, the specific samples 
that exhibited variation for each site was evaluated for each HV-type.  In this manner, SNPs that 
provided redundant discrimination were identified and removed from consideration.  Additional 
details relating to SNP selection considerations can be found in Coble (2004), Coble et al. 
(2004), Just et al. (2004), and Coble et al. (2005). 
 In selecting SNPs for assay development, we included the criterion that the SNPs not 
have the potential for phenotypic effect, i.e. amino acid changes in protein or structural changes 
in ribosomal or tRNAs  (however, just above we described an exception for the particularly 
useful SNP, 3010, in the 16S rRNA gene).  The basis for this criterion is that there are many 
diseases directly caused by mtDNA mutations or hypothesized to be correlated to variation in 
amino acid or structural RNA sequences (see www.mitomap.org).  Detailed discussion relating 
to this criterion are beyond the scope of this report, but are dealt with in detail in Budowle et al. 
(2005) and Coble et al. (2005).  AFDIL has made the practical determination that including non-
synonymous SNPs as targets would pose an unacceptably high probability of having to deal with 
issues of medical genetic counseling.  As described in Coble et al. (2005), and illustrated below, 
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the redundant nature of many discriminatory SNPs makes it possible to rely exclusively on 
synonymous or non-coding variation without losing much discrimination potential.  However, 
we list below additional non-synonymous discriminatory SNPs that could be employed for 
additional resolution. 
All selected SNPs for each population were organized into multiplex panels (Tables 6-8). 
Each panel targets specific HV-types, and when different HV-types were resolved by the same 
SNP targets, these were organized into the same panels when possible.  SNP panels were kept 
relatively small (six to eleven sites per panel) due to the complexity of optimizing multiplex 
PCR, and as such some HV-types are targeted by more than one SNP panel.  For example, 14 
target SNPs were identified for Caucasian HV-type H:1.  Caucasian multiplex panel A is the 
primary panel for type H:1 and contains the eleven sites with the greatest discriminatory power.  
Caucasian multiplex panel F contains the three remaining H:1 SNP targets, and can be used as a 
secondary panel for H:1 samples in the event that panel A did not provide the necessary 
discrimination. 
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Panel A Panel B Panel C Panel D Panel E Panel F Panel G Panel H 
477 477 72 482 4808 64 3826 4688 
3010 3010 513 5198 5147 4745 3834 11377 
4580 3915 4580 6260 9380 10211 4688 12795 
4793 5004 5250 9548 9899 10394 6293 13293 
5004 6776 11719 9635 11914 10685 7891 14305 
7028 8592 12438 11485 15067 11377 11533 16519 
7202 10394 12810 11914 16519 14470 12007   
10211 10754 14770 15355   14560 12795   
12858 11864 15833 15884   16390 15043   
14470 15340 15884 16368   14869 16390   
16519 16519 16519       16519   
                
11 PLEX 11 PLEX 11 PLEX 10 PLEX 7 PLEX 10 PLEX 11 PLEX 6 PLEX 
                
Targets: Targets: Targets Targets: Targets: Targets: Targets: Targets: 
H:1 (primary) H:2 (primary) V:1 (primary) J:1 (primary) J:4 V:1 (secondary) J:1 (secondary) K:1 
  H3 (primary) H:5 J:2 T:2 H:1 (secondary) J:3   
  H:6   K:2 T:3 H:2 (secondary) T:1   
      K:3 H:4 H:3 (secondary)     
 
Table 6. Caucasian Multiplex Panels 
59 non-redundant, discriminatory SNPs were organized into eight multiplex panels, ranging in size from 
six to eleven sites per panel.  HV-types that shared several discriminatory SNPs were grouped into the 
same panel when feasible.  Due to the large number of discriminatory sites identified for some HV-types, 
these HV-types are targeted by both a primary and a secondary multiplex panel.  Additionally, some 
discriminatory SNPs are shared by many HV-types and thus appear in several multiplex panels (i.e. 
16519). 
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Panel I Panel J Panel K Panel L Panel M Panel N 
3495 5063 6221 3852 4080 4655 
5252 6932 13617 7711 5580 6378 
6152 7424 13650 8155 7394 8751 
7424 7702 13980 11800 7915 10286 
12354 8206 15244 14182 11020 13197 
12603 8856 16399 15043 11254 14560 
13644 12732   16399 13884 15211 
13938 14566     16519 16519 
16519 16519         
            
9 PLEX 9 PLEX 6 PLEX 7 PLEX 8 PLEX 8 PLEX 
            
Targets: Targets: Targets: Targets: Targets: Targets: 
L2a:1 L1a:2 L2a:4 (secondary) L3:3 L1b:1 L1b:2 
L2a:4 (primary) L2a:5 (primary) L2a:5 (secondary) L3b:2 L2a:2 L2a:6 
  L2b:1   L3:2 L2a:3 L3e:2 
  L3e:1   L1a:1 L3e:4   
 
Table 7. African-American Multiplex Panels 
42 non-redundant, discriminatory SNPs were organized into six multiplex panels, ranging in size from six 
to nine sites per panel.  HV-types that shared several discriminatory SNPs were grouped into the same 
panel when feasible.  Due to the large number of discriminatory sites identified for some HV-types, these 
HV-types are targeted by both a primary and a secondary multiplex panel.  Additionally, some 
discriminatory SNPs are shared by many HV-types and thus appear in several multiplex panels (i.e. 
16519). 
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Panel O Panel P Panel R 
64 4790 493 
5081 5081 6719 
10595 6308 7241 
11314 13920 7262 
11653 14364 11440 
12696 15629 11989 
13350 15805 12696 
15229 16519 16519 
16391     
16519    
      
10 PLEX 8 PLEX 8 PLEX 
      
Targets: Targets: Targets: 
A2:1 A2:3 B2:1 
A2:2 D1:1 C1:2 
A2:6   J:5 
B2:2     
 
Table 8. Hispanic Multiplex Panels 
22 non-redundant, discriminatory SNPs were organized into three multiplex panels, ranging in size from 
eight to ten sites per panel.  HV-types that shared several discriminatory SNPs were grouped into the 
same panel when feasible.  Some discriminatory SNPs are shared by many HV-types and thus appear in 
several multiplex panels (i.e. 16519). 
  
 
 
 
 
The number of  SNPs meeting our criteria varied between the populations as well as with 
the number of samples sequenced for each HV-type (Tables 9-11).  For example, 241 Caucasian 
samples sequenced from 18 HV-types resulted in a total of 59 target SNPs.  A similar relative 
number of sites for assay development were identified for the African-American population (140 
samples sequenced from 20 HV-types resulted in 40 unique discriminatory sites).  However, 
relatively fewer sites for assay development were identified for US Hispanics (125 samples 
sequenced from 18 HV-types resulted in only 22 unique discriminatory sites). 
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 SNP Information 
HV-types % of Population Matching HV-type 
# of 
Samples 
Sequenced 
# of 
discriminatory, 
non-redundant 
SNPs per  
HV-type 
# 1st 
Codon 
Position
# 3rd 
Codon 
Position
# CR # Non-coding 
# 
coding**
H:1 7.92% 31 14 1 10 2 0 1 
H:2 2.05% 25 16 2 10 3 0 1 
H:3 1.03% 11 7 0 5 1 0 1 
H:4 0.54% 8 1 0 1 0 0 0 
H:5 1.03% 12 5 1 1 2 1 0 
H:6 0.91% 11 5 1 1 2 0 1 
H:7 0.66% 7 0 0 0 0 0 0 
J:1 1.21% 15 8 0 4 4 0 0 
J:2 0.66% 8 5 0 4 1 0 0 
J:3 0.79% 13 4 0 4 0 0 0 
J:4 0.36% 8 2 0 1 1 0 0 
T:1 1.33% 21 7 1 6 0 0 0 
T:2 0.60% 10 1 0 1 0 0 0 
T:3 0.66% 8 2 0 2 0 0 0 
V:1 1.21% 25 11 1 6 4 0 0 
K:1 1.09% 14 7 0 5 2 0 0 
K:2 0.60% 7 2 0 2 0 0 0 
K:3 0.60% 7 3 0 2 0 1 0 
  23.25% 241 59* 5* 44* 8* 1* 1* 
 
Table 9. Caucasian Whole Genome Sequencing Results  
A listing of the HV-types sequenced, the prevalence of each type in the population, the number of 
samples sequenced for each HV-type, the number of discriminatory, non-redundant SNPs for each HV-
type, and the genome location for each of the sites. 
* Totals listed for these columns may not equal the total of all values in the column.  This is due to the fact that 
some HV-types share the same discriminatory, non-synonymous SNPs (for example, 16519).  The total values 
reflect the total number of discriminatory, non-synonymous sites for the population. 
** One site, 3010, is located in the 16S rRNA gene. 
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 SNP Location 
HV-types % of Population Matching HV-type 
# of 
Samples 
Sequenced
# of 
discriminatory, 
non-redundant 
SNPs per  
HV-type 
# 1st 
Codon 
Position
# 3rd 
Codon 
Position 
# CR # Non-coding 
L0a:1 0.29% 4 1 0 1 0 0 
L0a:2 0.64% 4 2 0 1 1 0 
L1b:1 2.22% 14 4 0 4 0 0 
L1b:2 1.07% 5 1 1 0 0 0 
L2a:1 2.29% 10 5 0 5 0 0 
L2a:2 0.72% 4 3 0 2 1 0 
L2a:3 0.79% 4 3 0 1 1 1 
L2a:4 0.93% 10 10 0 8 2 0 
L2a:5 1.15% 16 8 0 6 2 0 
L2a:6 1.15% 10 4 0 3 1 0 
L2b:1 0.93% 8 4 0 3 1 0 
L2c:1 0.50% 4 2 0 2 0 0 
L3b:1 0.43% 3 0 0 0 0 0 
L3b:2 1.00% 5 4 0 3 1 0 
L3e:1 1.22% 12 4 0 4 0 0 
L3e:2 1.22% 8 3 0 3 0 0 
L3e:3 0.72% 3 0 0 0 0 0 
L3e:4 0.43% 3 1 0 0 0 1 
L3e:6 1.00% 8 3 0 2 1 0 
L3f:1 0.72% 5 0 0 0 0 0 
20 19.42% 140 42* 1* 38* 2* 1* 
 
Table 10. African-American Whole Genome Sequencing Results  
A listing of the HV-types sequenced, the prevalence of each type in the population, the number of 
samples sequenced for each HV-type, the number of discriminatory, non-redundant SNPs for each HV-
type, and the genome location for each of the sites. 
* Totals listed for these columns may not equal the total of all values in the column.  This is due to the fact that 
some HV-types share the same discriminatory, non-synonymous SNPs (for example, 16519).  The total values 
reflect the total number of discriminatory, non-synonymous sites for the population. 
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SNP Location 
HV-types % of Population Matching HV-type 
# of 
Samples 
Sequenced
# of 
discriminatory, 
non-redundant 
SNPs per  
HV-type 
# 1st 
Codon 
Position
# 3rd 
Codon 
Position 
# CR # Non-coding 
A2:1 3.57% 15 7 0 4 3 0 
A2:2 1.35% 7 4 0 3 1 0 
A2:3 1.35% 15 5 2 2 1 0 
A2:4 1.11% 4 0 0 0 0 0 
A2:5 0.56% 1 ***         
A2:6 0.56% 5 2 0 1 1 0 
B2:1 1.11% 7 2 0 2 0 0 
B2:2 0.63% 6 2 0 1 1 0 
C1:1 2.62% 12 0 0 0 0 0 
C1:2 1.74% 13 5 0 3 2 0 
C1:3 0.63% 3 0 0 0 0 0 
C1:4 0.56% 2 0 0 0 0 0 
D1:1 1.98% 11 5 1 3 1 0 
U5:1 0.56% 4 0 0 0 0 0 
K:4 2.06% 12 0 0 0 0 0 
J:5 0.79% 5 1 0 1 0 0 
L1b:3 0.63% 2 0 0 0 0 0 
L3e:5 0.56% 1 ***         
18 22.37% 125** 22* 2* 16* 4* 0* 
        
H:1 1.03% 
Cauc. 
common 
type, panels 
already 
designed.      
19 23.40% 156      
 
Table 11. Hispanic Whole Genome Sequencing Results  
A listing of the HV-types sequenced, the prevalence of each type in the population, the number of 
samples sequenced for each HV-type, the number of discriminatory, non-redundant SNPs for each HV-
type, and the genome location for each of the sites. The HV-type H:1 is common among Hispanics, 
however 31 H:1 samples had already been sequenced to identify discriminatory, non-redundant SNPs for 
the Caucasian common types.  As such, no additional H:1 samples were sequenced. 
* Totals listed for these columns may not equal the total of all values in the column.  This is due to the fact that 
some HV-types share the same discriminatory, non-synonymous SNPs (for example, 16519).  The total values 
reflect the total number of discriminatory, non-synonymous sites for the population. 
** Number represents the number of sequenced samples used to establish the total number of sites identified, not the 
total number of samples sequenced. 
*** Only one sample located for sequencing, no discriminatory, non-redundant sites were identified 
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It is of interest to compare the amount of discrimination potential contained within the 
entire mtGenome for common HV types within the three groups.  As noted above, fewer useful 
SNPs (according to our criteria) were discovered for Hispanics than in the other groups.  This is 
mirrored in the overall amount of variation present within the common HV types (Tables 12-14).  
In Hispanics, there are two sets of 9 individuals that match exactly over the entire mtGenome, 
compared to African Americans with two sets of three individuals, and Caucasians with four sets 
of four individuals.  Comparing the African American and Hispanic datasets, with roughly equal 
frequency distributions of common HV types, and similar sample sizes for each common HV 
type, we see 114/140 (81.4%) of the African American mtGenomes as unique, but only 72/125 
(57.6%) of the Hispanics mtGenomes resolved to unique types.  The factors that affect frequency 
mtDNA distributions within populations, especially in the case of recent continental 
immigration, are complex.  Nonetheless it may be reasonable to suppose that the extreme 
founder effect associated with Native American population expansion in the relatively recent 
past (~12,000-14,000 years ago) may account for the lack of variation in some of the common 
Hispanic HV types (that are predominantly Native American in origin). 
As discussed, among our basic selection criteria for target SNPs is that they do not have 
potential for phenotypic effect, so we have excluded non-synonymous variants.  It is useful, 
however, to evaluate this criterion in relation to the cost it carries with regard to lost 
discrimination potential.  Tables 12-14 show the amount of discrimination obtained by the use of 
the synonymous SNP panels only, compared to the discrimination obtained when non-
synonymous substitutions are included as well.  In both cases, we have excluded private 
polymorphisms that vary in only a single individual (which make no sense as targets for specific 
SNP assays), and the effect of that restriction can be seen by comparing to the discrimination 
44 
This document is a research report submitted to the U.S. Department of Justice. This report has not 
been published by the Department. Opinions or points of view expressed are those of the author(s) 
and do not necessarily reflect the official position or policies of the U.S. Department of Justice.
observed over the entire mtGenome (third panel of Tables 12-14).   In Caucasians, the 
synonymous SNP panels generate ~85% of the total discrimination that could be obtained from 
the synonymous and non-synonymous variation combined (again, excluding private 
polymorphisms).  Similarly, the African-American and Hispanic multiplex panels generate, 
respectively,  ~84% and ~95% of the discrimination that could be obtained if non-synonymous 
sites were included.  Tables 15-17 list the small number of non-private, non-synonymous sites 
that provide additional discrimination with respect to our selected multiplex panels, for each of 
the population groups.  
 
 
 
8 Multiplexes   
8 Multiplexes +                  
Non-Synonymous SNPs 
(excluding private polymorphisms) 
 Across Entire Genome 
# of types # individuals/type   # of types # individuals/type  # of types # individuals/type 
2 14   1 13  4 4 
1 9   1 12  5 3 
3 8   1 8  10 2 
2 7   2 7  190 1 
1 6   3 6      
3 5   6 4      
3 4   9 3      
8 3   23 2      
27 2   79 1      
55 1            
               
               
TOTAL: 106     TOTAL: 125    TOTAL: 209   
 
Table 12. Caucasian Discrimination 
Haplotype breakdown for the Caucasian dataset: 1) by the application of the eight multiplex panels, 2) by 
the application of the eight multiplex panels plus non-private, non-synonymous SNPs, and 3) across the 
entire genome.  Includes discrimination provided by HV sequences. 
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6 Multiplexes   
8 Multiplexes +                  
Non-Synonymous SNPs 
(excluding private polymorphisms) 
 Across Entire Genome 
# of types # individuals/type   # of types # individuals/type  # of types # individuals/type 
2 7   3 5  2 3 
1 6   1 4  10 2 
1 5   6 3  114 1 
4 4   23 2      
7 3   56 1      
18 2            
42 1            
               
TOTAL: 75     TOTAL: 89    TOTAL: 126   
 
Table 13. African-American Discrimination 
Haplotype breakdown for the African American dataset: 1) by the application of the six multiplex panels, 
2) by the application of the six multiplex panels plus non-private, non-synonymous SNPs, and 3) across 
the entire genome.  Includes discrimination provided by HV sequences. 
 
 
 
 
 
 
 
3 Multiplexes   
8 Multiplexes +                  
Non-Synonymous SNPs 
(excluding private polymorphisms) 
 Across Entire Genome 
# of types # individuals/type   # of types # individuals/type  # of types # individuals/type 
2 12   1 12  2 9 
1 7   1 11  1 5 
1 6   1 7  1 4 
6 4   1 6  2 3 
5 3   7 4  10 2 
11 2   3 3  72 1 
27 1   10 2      
      32 1      
               
TOTAL: 53     TOTAL: 56    TOTAL: 88   
 
Table 14. Hispanic Discrimination 
Haplotype breakdown for the Hispanic dataset: 1) by the application of the three multiplex panels, 2) by 
the application of the three multiplex panels plus non-private, non-synonymous SNPs, and 3) across the 
entire genome.  Includes discrimination provided by HV sequences. 
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Site: Variable in Types: 
1719 H:1; T:2 
1811 J:1 
2772 J:1; H:2 
4025 j:1 
4639 H:7; V:1 
5460 H:1 
8433 T:1; H:6 
8803 H:5 
8839 J:1 
8869 V:1 
15323 H:1; H:3 
15773 V:1, T:1 
15924 T:2; H:1 
 
Table 15. Caucasian Discriminatory Non-Synonymous Sites 
A listing of non-private, non-synonymous sites in US Caucasians that provide additional discrimination 
when combined with the selected multiplex panels and HV sequencing. 
 
 
 
 
 
Site: Variable in Types: 
731 L2a:5 
1719 L1b:1, L3e:6 
3866 L3b:2 
5563 L2c:1 
6261 L3e:2 
9804 L1b:2 
10454 L2a:6 
12172 L0a:2 
12906 L1b:1 
13790 L3b:1 
14766 L2a:5 
15431 L3e:1 
15617 L2a:6, L3e:2 
 
Table 16. African-American Discriminatory Non-Synonymous Sites 
A listing of non-private, non-synonymous sites in African Americans that provide additional 
discrimination when combined with the selected multiplex panels and HV sequencing. 
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Site: Variable in Types: 
3202 A2:1 
3316 B2:1; C1:2 
7444 A2:2 
7628 C1:1; C1:2 
6261 L3e:2 
9098 B2:1 
12223 B2:1; D1:1 
14178 B2:1 
15617 A2:1 
 
Table 17. Hispanic Discriminatory Non-Synonymous Sites 
A listing of non-private, non-synonymous sites in Hispanics that provide additional discrimination when 
combined with the selected multiplex panels and HV sequencing. 
 
 
 
 
 
Optimization and Testing of Caucasian Multiplex SNP Panels using the SNaPshot Platform 
 
 
The choice of a SNP platform must take into consideration the difficulties encountered 
when working with mtDNA.  mtDNA analysis is typically performed on highly degraded 
samples, and testing is often complicated by limited extract quantities.  These factors necessitate 
an assay that uses short amplicons, has extremely high sensitivity, and can be easily multiplexed.  
An additional important assay feature is the ability to detect low-level mixtures and 
heteroplasmy. A detection platform common to laboratories performing fluorescent fragment 
analysis for short tandem repeats (STRs) or mtDNA analysis is also desirable. 
We chose to focus on an allele-specific primer extension assay (ASPE), SNaPshot™ 
(Applied Biosystems), as the platform for the multiplex SNP assays.  The SNaPshot protocol 
uses fluorescently-labeled dideoxy terminator incorporation at the site of interest followed by 
detection on a capillary electrophoresis instrument (such as the Applied Biosystems 3100).  
Multiplexing is achieved by the varying the length of the extension primers (designed by the 
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scientist) which provides spatial separation in detection.  The SNaPshot assay uses small 
amplicons, can be multiplexed for ten or more SNPs, has high sensitivity, and good detection of 
mixture and heteroplasmy.  Initial work on the ASPE assay was done in collaboration with Peter 
Vallone (NIST), who performed the amplification and extension primer design, pristine DNA 
optimization, and sensitivity testing for multiplex panel A (Vallone et al. [2004]). 
Figure 9 provides an overview of the standard ASPE assay protocol from amplification 
through detection, and a detailed description of our protocol is described in Vallone et al. (2004).  
A 31-cycle, reverse-touchdown multiplex amplification is performed in a total volume of 15µl.  
PCR reaction cleanup to remove unincorporated dNTPs and PCR primers is accomplished by the 
addition of Exonuclease I and Shrimp Alkaline Phosphatase (SAP).  The 25-cycle multiplex 
SNaPshot primer extension reaction combines the commercially available SNaPshot Ready 
Reaction Mix™ (Applied Biosystems) with PCR products and extension primers in a 10µl 
reaction.  A final clean-up is accomplished by a SAP incubation.  Fluorescent detection is 
performed on an Applied Biosystems 3100 capillary electrophoresis sequence detection system 
and the data analyzed in GeneScan v3.7 and Genotyper v3.7 or GeneMapperID v3.1(all Applied 
Biosystems).  Appendix III describes all current thermal cycling conditions and 3100 injection 
parameters. 
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Figure 9.  Overview of allele-specific primer extension assay using the SNaPshot platform. 
The five steps of the assay, including amplification, PCR reaction clean-up, extension, extension reaction 
cleanup, and detection/analysis.  The extension reaction is shown here in more detail. An extension 
primer anneals to the target strand immediately 3’ to the site of interest.  A single, fluorescently-labeled 
dideoxy terminator is incorporated at the SNP site and the extension is terminated.  The result is an oligo 
of a specific size (based on the length of the poly-T tail), the fluorescent label for which identifies the 
nucleotide at the site of interest. 
 
 
 
 
 The development and optimization of working assays for the multiplex panels was 
accomplished through a step-wise approach.  The first step consisted of amplification and 
extension primer design, and was followed first by singleplex and then multiplex testing of the 
amplification and extension primers.  Once an optimized assay had been developed using pristine 
positive controls, sensitivity testing and then tests on mixtures were conducted.  Finally, the 
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assays were tested on degraded samples, and the assay conditions optimized to create a new, 
degraded samples protocol. 
 
Step 1: Amplification and Extension Primer Design and Purchase 
 Amplification primer design was a critical component of the SNP assay design and 
optimization.  The requirement that the SNP panels be functional for highly degraded samples 
dictated a small amplicon size, preferably 150 base pairs or smaller.  Eliminating approximately 
30bp upstream and downstream of the SNP site for later extension primer selection, about 50bp 
of template sequence further upstream and downstream were entered into the web-based program 
Primer3 (Rozen and Skaletsky) for forward and reverse amplification primer selection.  This 
primer selection strategy is depicted in Figure 10.  The default Primer3 settings (Table 18) were 
used to select the best candidate amplification primers.  These primers were then compared to 
our whole genome datasets to select primers for which the binding sites would avoid highly 
polymorphic sites in the target populations.  If, based on desired amplicon size, no suitable 
primers could be identified that would avoid highly polymorphic positions, degenerate primers 
were designed. 
 Extension primers were also selected using the Primer3 program with the default settings 
(Table 18).  The nature of the SNaPshot™ single-base extension reaction restricts the extension 
primer to one of two positions: the sequence immediately 5’ to the SNP on either the forward or 
the reverse strand.  For each SNP, approximately 30 bases upstream of the site on both the 
forward and reverse strands were entered into Primer3 for consideration (Figure 10).  While 
many of the extension primers selected were excellent candidate primers, the position restriction 
on occasion forced a choice between two undesirable primers. 
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Figure 10. Amplification and Extension Primer Selection Strategy 
Extension primers were selected from the first ~30bp upstream or downstream from each SNP site, and 
amplification primers were selected from the next ~50bp upstream and downstream.  Amplicons range in 
size but most are 150bp or smaller. 
 
 
 
Max 3' Stability 
 
9 Max Primer TM 63
Max Mispriming 12  Min Primer GC% 20
Min Primer Size 18  Max Primer GC % 80
Opt Primer Size 20  Max Self-Complimentarity 8 
Max Primer Size 27  Max 3' Self-Complimentarity 3 
Min Primer TM 57  Max Poly-X 5 
Opt Primer TM 60    
 
 
Table 18. Primer3 Default Settings 
The default Primer3 settings were used for primer selection. 
 
 
 
 
One of the complexities to multiplexing is the potential for significant primer-primer 
interactions. Once all amplification and extension primers were designed, the sequences for each 
multiplex panel were run through NIST’s AutoDimer program (Vallone and Butler, 2004) to 
check for such potential interactions.  All sequences were compared using the default program 
settings.  On occasion, primer pairs were identified that would be likely to form primer-dimers, 
and these primers were subsequently redesigned.  Appendix IV lists the final amplification and 
primer sequences for all 8 Caucasian SNP multiplexes. 
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 Issues with primer quality control were problematic throughout the project and resulted in 
the purchase of oligos from several different sources. Over the course of the 5-year project, 
primers were purchased from three different companies (Qiagen Operon, MWG Biotech, and 
Proligo) and with different purification options (none, HPLC, and PAGE) with varying degrees 
of success in terms of the primer quality control.  Primers are currently purchased from Proligo 
in either unpurified 10 O.D. batches (amplification primers) or PAGE-purified 1 O.D. batches 
(extension primers).  
One of the significant primer quality control issues encountered was variation, sometimes 
by as much as 40%, in the concentration of the primer stocks.  Similar variation was observed 
whether oligos were received lyophilized or in solution.  To correct for this variation, oligos 
were ordered lyophilized and subsequently resuspended in-house to ~200µM based on the 
concentration indicated by the manufacturer. Actual concentrations were determined via UV 
absorbance read at 260nm on a Tecan™ Genios™ plate reader, using the molar extinction 
coefficient for each oligo.  The concentrations were then adjusted to100µM for storage at -20˚C. 
 
Step 2: Primer Testing 
 The second step in the multiplex assay development was the testing of the newly 
designed amplification and extension primers. Amplification primers were tested in singleplex at 
1µM final reaction concentrations, and visualized on 1% agarose gels.  Extension primers were 
tested in singleplex at 0.5µM final reaction concentrations.  Singleplex extension products were 
detected on an Applied Biosystems 3100 Genetic Analyzer, and the resulting electropherograms 
analyzed in Genescan™ v3.7 and GenoTyper™ v.3.7, or GeneMapperID™ v3.1 (all Applied 
Biosystems).  The electropherograms were reviewed to detect any potential problematic results, 
to include: 1) the presence of any peaks other than the expected peak, 2) the presence of 
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significant N-X or N+X peaks, indicative of poor extension primer quality, 3) unexpected 
migration of the expected peak that might cause overlap and incorrect allele assignment with a 
peak for another SNP in the multiplex, 4) uneven signal intensities between variants for each 
SNP, and 5) low signal intensity.  Primer issues identified in singleplex testing resulted in some 
primer re-order and/or redesign. 
 Following successful testing of all primers in singleplex, multiplex amplification with 
singleplex extension reactions was attempted.  For each multiplex panel, the amplification 
primers were initially tested at equimolar concentrations.  For example, Multiplex A has 22 
amplification primers (11 each forward and reverse primers), and each primer was at a 
concentration of 4.55 µM in the multiplex amplification primer mix (0.91 µM final reaction 
concentration).  The resulting electropherograms were examined for, in particular, strong 
differences in extension product signal intensity between the multiplex amplification results 
compared with the previous singleplex amplification results.  While some decrease in signal 
intensity might expected due to the competitive nature of multiplex PCR, any unusual changes in 
signal intensity were investigated.  Occasionally, problems with signal intensity resulted in 
primer re-order and/or re-design. 
 The final step in primer testing was multiplex amplification combined with multiplex 
extension.  For the initial testing, all extension primers were combined into a mix with a 0.5µM 
final concentration for each primer.  The resulting electropherograms were examined for two 
critical potential problems: 1) relative signal strength, and 2) extraneous extension peaks.  1) 
Relative signal strength:  Though amplification and extension primers were carefully designed, 
there was often variation in relative signal strength between sites as a result of varied primer 
binding efficiency in both the amplification and extension reactions.  Attempts were made to 
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balance the signal strength for each site in a multiplex panel by adjusting the concentration of the 
extension primer in the multiplex primer mix.  When sufficient balancing could not be obtained 
in this manner, forward, reverse, or both amplification primer concentrations were adjusted in the 
multiplex primer mix.  When signal strength still failed to achieve the minimum balance desired, 
amplification and/or extension primers were re-ordered or redesigned.  2) Extraneous extension 
peaks:  When peaks were observed on the electropherogram that did not appear to correspond to 
a particular SNP, experiments were performed to determine the cause.  Frequently, through 
duplex testing of the amplification and/or extension primers, the extraneous peak was identified 
as resulting from a primer-primer interaction that had not been identified during the primer 
design phase.  In these cases, primers were re-designed and re-tested to attempt to eliminate the 
extraneous peaks.  In some cases however, the extraneous peaks appeared to be primer lot 
dependant.  In such situations, the primers were either re-ordered, or if the extraneous peak 
would cause no error in allele calling, the extraneous peak was noted and recorded as a known 
artifact specific to a particular lot of primer. 
 Figures 11-17 show the balanced multiplex results for Caucasian panels A-C and E-H.  
Tables 19-25  list the sites in each multiplex, and the expected position and color for each peak.  
Appendix IV lists the final primer sequences, and the final primer concentrations, for multiplex 
panels A-C and E-H.  Caucasian panel D is still undergoing some optimization and is not yet 
ready for further testing. 
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Figure 11. Multiplex Panel A 
Plots of fragment size (x-axis) relative to –120LIZ size standard (Applied Systems) and relative 
fluorescent units (RFUs, y-axis).  Results are typical for Multiplex A following extension primer 
concentration balancing (Appendix II lists the final primer concentrations). 
 
 
 
 
 
 
 
 
Multiplex A 
Site Anderson Variant Variant 2 Size Range 
3010 F Blue / G Green / A   20.5-23 
4793 R Red / A Black / G   24-26.5 
10211 R Blue / C Green / T   31-33 
5004 F Red / T Black / C   33.5-35.5 
7028 F Black / C Red / T   39-41 
7202 F Green / A Blue / G   42-44.5 
16519 R Green / T Blue / C Red / A 48-50 
12858 F Black / C Red / T   50.5-52.5 
4580 R Black / G Red / A   55-56.5 
477 F Red / T Black / C   57.5-59.5 
14470 R Green / T Red / A Blue / C 63.5-66 
 
Table 19. Multiplex Panel A 
Lists the sites, the possible variants, their dye colors on the resulting electropherogram, and the 
approximate nucleotide size as it will appear following GeneScan™ analysis. 
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Figure 12. Multiplex Panel B 
Plots of fragment size (x-axis) relative to –120LIZ size standard (Applied Systems) and relative 
fluorescent units (RFUs, y-axis).  Results are typical for Multiplex B following extension primer 
concentration balancing (Appendix II lists the final primer concentrations). 
 
 
 
 
 
 
 
 
Multiplex B 
Site Anderson Variant Variant 2 Size Range 
3010 F Blue / G Green / A   20-23 
477 R Green / T Blue / C   28-31 
15340 R Red / A Black / G   31-33 
5004 F Red / T Black / C   33.5-35.5 
6776 F Red / T Black / C   39-41 
8592 R Black / G Red / A   43.5-45.5 
16519 R Green / T Blue / C Red / A 48.5-50 
10394 F Black / C Red / T   51-52.5 
10754 F Green / A Black / C   54-55.5 
11864 F Red / T Black / C   58-60 
3915 F Blue / G Green / A   61.5-64 
 
Table 20. Multiplex Panel B 
Lists the sites, the possible variants, their dye colors on the resulting electropherogram, and the 
approximate nucleotide size as it will appear following GeneScan™ analysis. 
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Figure 13. Multiplex Panel C 
Plots of fragment size (x-axis) relative to –120LIZ size standard (Applied Systems) and relative 
fluorescent units (RFUs, y-axis).  Results are typical for Multiplex C following extension primer 
concentration balancing (Appendix II lists the final primer concentrations). 
 
 
 
 
 
 
 
 
 
Multiplex C 
Site Anderson Variant Position 
72 R Green / T Blue / C 20 / 22 
513 F Blue / G Green / A 25 / 27 
5250 F Red / T Black / C 31 / 32 
11719 R Black / G Red / A 36 / 37 
12438 R Green / T Blue / C 39 / 40 
12810 R Red / A Black / G 44 / 45 
16519 R Green / T Blue / C 48 / 49 
14770 F Black / C Red / T 50 / 51 
4580 R Black / G Red / A 55 / 56 
15833 F Black / C Red / T 58 / 59 
15884 F Blue / G Green / A 62 / 63 
 
Table 21. Multiplex Panel C 
Lists the sites, the possible variants, their dye colors on the resulting electropherogram, and the 
approximate nucleotide size as it will appear following GeneScan™ analysis. 
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Figure 14. Multiplex Panel E 
Plots of fragment size (x-axis) relative to –120LIZ size standard (Applied Systems) and relative 
fluorescent units (RFUs, y-axis).  Results are typical for Multiplex E following extension primer 
concentration balancing (Appendix II lists the final primer concentrations). 
 
 
 
 
 
 
 
 
Multiplex E 
Site Anderson Variant Position 
4808 F Black / C Red / T 23 / 24 
5147 F Blue / G Green / A 55 / 56 
9380 F Blue / G Green / A 31 / 32 
9899 F Red / T Black / C 36 / 37 
11914 R Black / C Red / T 52 / 53 
15067 F Red / T Black / C 43 / 44 
16519 R Green / T Blue / C 49 / 50 
 
Table 22. Multiplex Panel E 
Lists the sites, the possible variants, their dye colors on the resulting electropherogram, and the 
approximate nucleotide size as it will appear following GeneScan™ analysis. 
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Figure 15. Multiplex Panel F 
Plots of fragment size (x-axis) relative to –120LIZ size standard (Applied Systems) and relative 
fluorescent units (RFUs, y-axis).  Results are typical for Multiplex F following extension primer 
concentration balancing (Appendix II lists the final primer concentrations). 
 
 
 
 
 
 
 
 
 
Multiplex F 
Site Anderson Variant 1 Variant 2 Position 
14869 F Blue / G Green / A Black / C 19 / 20 / 20 
4745 F Green / A Blue / G   25 / 26 
10685 R Black / G Red / A   29 / 30 
10394 F Black / C Red / T   35 / 36 
10211 R Blue / C Green / T   40 / 41 
11377 R Black / G Red / A   44 / 45 
14560 F Blue / G Green / A   47 / 48 
16390 R Black / G Red / A   51 / 52 
14470 R Green / T Blue / C Red / A 56 / 57 / 57 
64 F Black / C Red / T   61 / 62 
 
Table 23. Multiplex Panel F 
Lists the sites, the possible variants, their dye colors on the resulting electropherogram, and the 
approximate nucleotide size as it will appear following GeneScan™ analysis. 
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Figure 16. Multiplex Panel G 
Plots of fragment size (x-axis) relative to –120LIZ size standard (Applied Systems) and relative 
fluorescent units (RFUs, y-axis).  Results are typical for Multiplex G following extension primer 
concentration balancing (Appendix II lists the final primer concentrations). 
 
 
 
 
 
 
 
 
 
Multiplex G 
Site Anderson Variant Position 
3834 R Black / G Red / A 23 / 25 
3826 F Red / T Black / C 27 / 28 
6293 F Red / T Black / C 30 / 31 
7891 R Blue / C Green / T 34 / 35 
12007 F Blue / G Green / A 38 / 39 
11533 R Blue / C Green / T 43 / 44 
4688 F Red / T Black / C 46 / 47 
16519 F Red / T Black / C 49 / 50 
16390 R Black / G Red / A 52 / 51 
12795 F Blue / G Green / A 57 / 58 
15043 F Blue / G Green / A 60 / 61 
 
Table 24. Multiplex Panel G 
Lists the sites, the possible variants, their dye colors on the resulting electropherogram, and the 
approximate nucleotide size as it will appear following GeneScan™ analysis. 
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Figure 17. Multiplex Panel H 
Plots of fragment size (x-axis) relative to –120LIZ size standard (Applied Systems) and relative 
fluorescent units (RFUs, y-axis).  Results are typical for Multiplex H following extension primer 
concentration balancing (Appendix II lists the final primer concentrations). 
 
 
 
 
 
 
Multiplex H 
Site Anderson Variant Position 
13293 Blue / C Green / T 25.5 / 27 
14305 Black / G Red / A 29 / 30 
4688 Red / T Black / C 34.5 / 33 
12795 Blue / G Green / A 40 / 41 
11377 Black / G Red / A 44 / 45 
16519 Red / T Black / C 50 / 49 
 
Table 25. Multiplex Panel H 
Lists the sites, the possible variants, their dye colors on the resulting electropherogram, and the 
approximate nucleotide size as it will appear following GeneScan™ analysis. 
 
 
 
 
Step 3: Sensitivity Testing 
 Once each multiplex was optimized, each panel was tested in regards to its sensitivity.  
Because these SNP assays are designed specifically for use on highly degraded samples, it is 
especially important that they have high sensitivity, preferably achieving full results with less 
62 
This document is a research report submitted to the U.S. Department of Justice. This report has not 
been published by the Department. Opinions or points of view expressed are those of the author(s) 
and do not necessarily reflect the official position or policies of the U.S. Department of Justice.
than 10pg of genomic DNA.  A dilution series from at least two different positive controls was 
run for each Caucasian multiplex panel.  The dilution series concentrations ranged from 500pg to 
0.1pg.  Figures 18-24 show the sensitivity results for Caucasian multiplex panels A-C and E-H. 
The figure for each multiplex shows typing results typical of 50pg genomic DNA, 10pg genomic 
DNA, and then the lowest concentration at which full typing was reproducibly obtained for that 
multiplex.  The threshold for calling a peak was set at 100 relative fluorescent units (rfu).  Full 
results were consistently obtained to 3pg genomic DNA or less, with some multiplexes sensitive 
to less than 1pg.  
 
 
 
 
 
 
Figure 18. Sensitivity for Multiplex A.   
Plots nucleotide size (x-axis) relative to –120LIZ size standard (Applied Systems) and relative fluorescent 
units (RFUs, y-axis). All 11 multiplexed sites were typed to 1pg. 
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Figure 19. Sensitivity for Multiplex B.   
Plots nucleotide size (x-axis) relative to –120LIZ size standard (Applied Systems) and relative fluorescent 
units (RFUs, y-axis). All 11 multiplexed sites were typed to 1pg. 
 
 
 
 
 
Figure 20. Sensitivity for Multiplex C.  
Plots nucleotide size (x-axis) relative to –120LIZ size standard (Applied Systems) and relative fluorescent 
units (RFUs, y-axis). All 11 multiplexed sites were typed to 0.5pg. 
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Figure 21. Sensitivity for Multiplex E.   
Plots nucleotide size (x-axis) relative to –120LIZ size standard (Applied Systems) and relative fluorescent 
units (RFUs, y-axis). All 7 multiplexed sites were typed to 3pg. 
 
 
 
 
 
 
Figure 22. Sensitivity for Multiplex F.   
Plots nucleotide size (x-axis) relative to –120LIZ size standard (Applied Systems) and relative fluorescent 
units (RFUs, y-axis).  All 10 multiplexed sites were typed to 3pg. 
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Figure 23. Sensitivity for Multiplex G.  
Plots nucleotide size (x-axis) relative to –120LIZ size standard (Applied Systems) and relative fluorescent 
units (RFUs, y-axis).  All 11 multiplexed sites were typed to 3pg. 
 
 
 
 
 
 
 
Figure 24. Sensitivity for Multiplex H.  
Plots nucleotide size (x-axis) relative to –120LIZ size standard (Applied Systems) and relative fluorescent 
units (RFUs, y-axis).  All 6 multiplexed sites were typed to 3pg. 
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Step 4: Mixture Testing 
 Following sensitivity testing, each multiplex was analyzed in regards to 
mixture/heteroplasmy detection.  For each multiplex, samples were identified which would 
produce mixtures at two or more sites.  The samples were quantified by an in-house Alu-repeat 
Taqman assay, and then the concentrations for each sample were normalized so that the 
concentrations for each extract were approximately equal.  The samples were mixed in the 
following ratios for mixture testing: 100:0, 90:10, 80:20 (or 70:30), 50:50, 20:80 (or 30:70), 
10:90, and 0:100.  All mixtures to the 10% level were successfully resolved for each multiplex 
under standard reaction conditions, with the exception of one site in Multiplex E.  Figures 25-31 
show mixtures results for each multiplex at 90:10 and 50:50 ratios.   In general, the 
electropherogram peaks resulting from ddG incorporation (blue) exhibited a stronger signal than 
ddA incorporation (green).  As such, 50:50 mixtures do not show even signal intensity for 
ddG/ddA mixtures. 
 As discussed in one of our publications (Vallone et al., 2004), the peak height ratios for 
mixed samples have not been characterized well enough to permit a determination of the exact 
mixture ratio.  An additional complication with the SNaPshot assay is the uneven signal intensity 
for the ddG/ddA mixtures.  This system is more than sufficient, however, for identifying a mixed 
sample or a heteroplasmic SNP.  Further, the inability to determine an exact mixture ratio is not 
limited to this assay, it is a known problem in mtDNA sequencing as well. 
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Figure 25.  Mixtures at 4 SNPs for Multiplex A.  
Plots nucleotide size (x-axis) relative to –120LIZ size standard (Applied Systems) and relative fluorescent 
units (RFUs, y-axis).  Mixture ratios shown are 90:10 and 50:50. 
 
 
 
 
 
 
Figure 26.  Mixtures at 4 SNPs for Multiplex B.  
Plots nucleotide size (x-axis) relative to –120LIZ size standard (Applied Systems) and relative fluorescent 
units (RFUs, y-axis).  Mixture ratios shown are 90:10 and 50:50. 
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Figure 27.  Mixtures at 7 SNPs for Multiplex C.  
Plots nucleotide size (x-axis) relative to –120LIZ size standard (Applied Systems) and relative fluorescent 
units (RFUs, y-axis).  Mixture ratios shown are 90:10 and 50:50. 
 
 
 
 
 
Figure 28.  Mixtures at 3 SNPs for Multiplex E.  
Plots nucleotide size (x-axis) relative to –120LIZ size standard (Applied Systems) and relative fluorescent 
units (RFUs, y-axis).  Mixture ratios shown are 90:10 and 50:50. 
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Figure 29.  Mixtures at 3 SNPs for Multiplex F.  
Plots nucleotide size (x-axis) relative to –120LIZ size standard (Applied Systems) and relative fluorescent 
units (RFUs, y-axis).  Mixture ratios shown are 90:10 and 50:50. 
 
 
 
 
 
 
 
Figure 30.  Mixtures at 4 SNPs for Multiplex G.  
Plots nucleotide size (x-axis) relative to –120LIZ size standard (Applied Systems) and relative fluorescent 
units (RFUs, y-axis).  Mixture ratios shown are 90:10 and 50:50. 
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Figure 31.  Mixtures at 3 SNPs for Multiplex H.  
Plots nucleotide size (x-axis) relative to –120LIZ size standard (Applied Systems) and relative fluorescent 
units (RFUs, y-axis).  Mixture ratios shown are 90:10 and 50:50. 
 
 
 
 
Step 5: Degraded Samples Testing 
 We tested the multiplex panels on several non-probative extracts typical of AFDIL 
degraded skeletal mtDNA cases (standard STR typing failed to give results) to test the multiplex 
panels on degraded samples.  Caucasian Multiplex A, being the first multiplex panel completed, 
was the first to be run on any degraded samples (Figure 32).  Initial results at standard 
amplification conditions were poor, and most samples had only a few sites the exceeded the 
100rfu threshold.  Additional experimentation to increase success included increased reaction 
volume, decreased extract concentration, and increased Taq polymerase concentration.  The 
final, optimized reaction conditions for degraded samples incorporates all of these modified 
conditions into a 25µl total volume, increased Taq concentration, degraded samples protocol (as 
opposed to the typical 15µl total volume standard reaction protocol, Table 26), and has resulted 
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in full typing on all degraded extracts thus far for all multiplexes tested (Figures 32-38) (Vallone 
et al., 2004).  A single exception to this was site 3915 for Multiplex B, for which primer quality 
control issues prevented typing at either reaction volume prior to the completion of this report. 
 
 
 
 
Components 25ul Rxn 
1X 
15ul Rxn 
1X 
Taq Gold PCR Buffer 2.5ul 1.5ul 
dNTP’s 2.5ul 1.5ul 
BSA 1.25ul 0.75ul 
MgCl2 2.0ul 1.25ul 
Taq Gold 1.25ul 0.5ul 
Primer Mix 5.0ul 3.0ul 
dH20 9.5ul 4.5ul 
Total volume per reaction 24.0ul 13.0ul 
Extract Volume to be Added 1.0ul 2.0ul 
 
 
Table 26. Standard and Degraded Samples Amplification Reaction Volumes. 
The 15µl total volume reaction with standard Taq polymerase concentration is the standard protocol for 
pristine DNA extracts.  The modified 25µl total volume reaction with increased Taq polymerase 
concentration is the protocol optimized for degraded samples. 
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Figure 32. A degraded sample typed for Multiplex A using the 15 and 25µl protocols.   
Plots of fragment size (x-axis) relative to –120LIZ size standard (Applied Systems) and relative 
fluorescent units (RFUs, y-axis).  Only 4 sites exceeded the 100rfu threshold using the 15µl total reaction 
volume standard protocol, however all 11 sites in the multiplex could be typed using the modified 25µl 
total reaction volume, increased Taq polymerase concentration protocol. 
 
 
 
 
 
 
Figure 33. A degraded sample typed for Multiplex B using the 15 and 25µl protocols.   
Plots of fragment size (x-axis) relative to –120LIZ size standard (Applied Systems) and relative 
fluorescent units (RFUs, y-axis). 9 of 11 sites exceeded the 100rfu threshold using the 15µl total reaction 
volume standard protocol, and 10 of 11 sites in the multiplex could be typed using the modified 25µl total 
reaction volume, increased Taq polymerase concentration protocol.  The single remaining site that could 
not be typed at either reaction volume was the result of a poor primer lot, and additional runs will confirm 
typing of this site at the 25 µl reaction volume. 
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Figure 34. A degraded sample typed for Multiplex C using the 15 and 25µl protocols.   
Plots of fragment size (x-axis) relative to –120LIZ size standard (Applied Systems) and relative 
fluorescent units (RFUs, y-axis).  No sites exceeded the 100rfu threshold using the 15µl total reaction 
volume standard protocol, however all 11 sites in the multiplex could be typed using the modified 25µl 
total reaction volume, increased Taq polymerase concentration protocol. 
 
 
 
 
 
 
Figure 35. A degraded sample typed for Multiplex E using the 15 and 25µl protocols.   
Plots of fragment size (x-axis) relative to –120LIZ size standard (Applied Systems) and relative 
fluorescent units (RFUs, y-axis).  Five of six multiplexed sites exceeded the 100rfu threshold using the 
15µl total reaction volume standard protocol, however all six sites in the multiplex could be typed using 
the modified 25µl total reaction volume, increased Taq polymerase concentration protocol. 
74 
This document is a research report submitted to the U.S. Department of Justice. This report has not 
been published by the Department. Opinions or points of view expressed are those of the author(s) 
and do not necessarily reflect the official position or policies of the U.S. Department of Justice.
 
Figure 36. A degraded sample typed for Multiplex F using the 15 and 25µl protocols.   
Plots of fragment size (x-axis) relative to –120LIZ size standard (Applied Systems) and relative 
fluorescent units (RFUs, y-axis).  Only three of the 10 multiplexed sites exceeded the 100rfu threshold 
using the 15µl total reaction volume standard protocol, however all 10 sites in the multiplex could be 
typed using the modified 25µl total reaction volume, increased Taq polymerase concentration protocol. 
 
 
 
 
 
 
 
Figure 37. A degraded sample typed for Multiplex G using the 15 and 25µl protocols.   
Plots of fragment size (x-axis) relative to –120LIZ size standard (Applied Systems) and relative 
fluorescent units (RFUs, y-axis).  Seven of the 11 multiplexed sites exceeded the 100rfu threshold using 
the 15µl total reaction volume standard protocol, however all 11 sites in the multiplex could be typed 
using the modified 25µl total reaction volume, increased Taq polymerase concentration protocol. 
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Figure 38. A degraded sample typed for Multiplex H using the 15 and 25µl protocols.   
Plots of fragment size (x-axis) relative to –120LIZ size standard (Applied Systems) and relative 
fluorescent units (RFUs, y-axis).  Full typing was obtained using both the 15µl total reaction volume 
standard protocol and the modified 25µl total reaction volume, increased Taq polymerase concentration 
protocol. 
 
 
 
 
Casework Application: 
Multiplex panel A has now been used to assist in the resolution of multiple AFDIL cases 
in which CR sequencing alone did not give sufficient discrimination.  The most common 
situation where the SNP panel has been applied are cases where CR sequencing showed only a 
single difference between samples.  AFDIL reporting guidelines, typical for forensic labs, 
require at least two mtDNA sequence differences in order to report an exclusion.  In other 
instances, the SNP panel testing has permitted both reassociation of unknown samples, and 
exclusion of references.  Figure 39 depicts a typical example where Multiplex A typing was able 
to resolve a case by revealing an additional sequence difference, permitting a definitive exclusion 
of one reference family, and strengthening the evidentiary significance of a match with another 
reference family.  
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Ref 2 matches the case samples 
Figure 39.  Multiplex A applied to an AFDIL missing person’s case.  
HVI/HVII sequencing on 3 case samples matched one reference family, but differed from a second 
reference family by only a single polymorphism (+/-334C).  AFDIL policy dictates that an exclusion 
cannot be made on the basis of a single difference, and thus the case would have been reported as 
“inconclusive”.  SNP typing using Multiplex A provided resolution by identifying an additional position 
at which the mismatching reference differed from the case samples (+/- 14470A). 
 
 
 
 
SNP Databasing 
 
 
 284 Caucasian population samples (source: NIST) were typed for seven Caucasian 
multiplex panels (A-C and E-H). Amplification set-up was performed in a 96-well format on a 
Corbett CAS single-probe instrument, and most post-PCR set-ups were performed in 96-well 
format on an 8-probe Tecan Genesis workstation.  Detection was performed as previously 
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described on an Applied Biosystems 3100.   For standard databasing, amplification thermal 
cycling parameters were decreased to a 26-cycle protocol.  Some samples, however, were 
amplified with a 31-cycle amplification protocol due to low sample concentrations. In addition, 
some samples required longer or shorter injection times than the standard 13-second injection. 
 Sample analysis was performed in GeneMapper ID v3.2 (Applied Biosystems).  Custom 
panels and bin sets were designed for each multiplex from samples previously tested and a set of 
analysis parameters (Table 27) was determined for analysis of all database samples.  Following a 
structure similar to that described for sequencing, data analysis involved confirmation by at least 
two scientists , and a total of three levels of review.  Primary and Secondary analyses were 
performed in GeneMapper, then imported into a custom Microsoft Excel macro for comparison.  
Once any discrepancies were resolved, the data was then exported to a secure Microsoft Access 
database for analysis of the results and long-term storage.  Custom queries within Access were 
used to compile the results of the entire database. 
In the course of databasing, null alleles were detected for a small number of samples for 
various multiplexes.  For the NIST database samples that have not been sequenced for the 
mtGenome, we don’t know the cause for the null alleles.  However, past experience indicates 
that null alleles can readily result from mutation in the extension primer binding site.  We have 
also observed that mutations in amplification primer binding sites can have large effects on 
signal strength, and this might also be a cause of the null alleles.  Care was taken in selection of 
SNPs and primers to avoid binding site polymorphisms within the target common HV types, 
however random HV types, for which the multiplexes were not designed, could well harbor 
polymorphisms.  For unknown reasons, 8 database samples did not produce full profiles for 
Multiplex C.  In the presentation of results that follows, we omit samples that had either null 
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alleles or incomplete typing;  this accounts for slight variation in sample sizes reported for the 
different multiplexes. 
 
ANALYSIS PARAMETERS 
General Analysis Type SNaPshot 
Allele Allele Cut-off value 0.01 
Algorithm Basic 
Blue 100 Red 100
Green 100 Orange 50 
Peak Detector 
Minimum Peak Heights (RFUs)
Yellow 100       
HM min peak height 100Signal Level 
HT min peak height 100
Heterozygote balance Min peak height ratio 0.3 
Peak morphology Max peak width (bps) 1.5 
Pull-up peak Pull-up ratio 0.1 
Allele number Max expected alleles 1 
Peak Quality 
SNP Double peak 0.5 
Spectral pull-up 0.5 Control Concordance 0.5 
Broad peak 0.5 Low peak height 0.5 
Narrow bin 0.5 Off-scale 0 
Quality Flag Settings 
Double peak 0 Peak Height Ratio 0.5 
Range: Pass Low Quality 
Sizing Quality 0.75-1.0 0.0-0.25 
Quality Flags 
PQV Thresholds 
Genotype Quality 0.75-1.0 0.0-0.25 
 
Table 27. GeneMapperID ID v3.2 Analysis Parameters. 
 
 
  
 
Figures 40-46 depict the breakdown of SNP-types when each multiplex panel is applied 
to a set of random Caucasian population samples. A SNP-type is defined here as the profile 
generated using only a single multiplex panel, and excluding HV sequence information. 
Multiplex A (Figure 40), targeting HV-type H:1, provides the greatest discrimination among a 
set of random samples.  Its application results in 17 SNP-types, and no single type has a 
frequency greater than 30%.  This result is not unexpected given the high frequency of the H:1 
type in the Caucasian population (~7%) and in our dataset (~6%, or 17 samples out of the 281 
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samples data based for Multiplex A).  Multiplex F (Figure 44), the secondary multiplex for HV-
types H:1, H:2, H:3, and V:1, provides the least stand-alone discrimination among a set of 
random samples.  Though application of this multiplex results in 13 SNP-types, a single SNP-
type occurs with a frequency of nearly 90% and more than half of the SNP-types occur with a 
frequency of less than 1%.  This result is also not unexpected given that Multiplex F is 
comprised of the second tier of discriminatory SNPs identified for the four HV-types the panel 
targets.  
 
Figure 40.  Multiplex A applied to 281* Caucasian samples. 
The 11 multiplexed SNP sites of Multiplex A produced 17 SNP-types, 3 of which were unique. 
*Samples with null alleles (3) were not used in the analysis of this panel. 
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Figure 41.  Multiplex B applied to 279* Caucasian samples. 
The 10+ multiplexed SNP sites of Multiplex B produced 9 SNP-types, 1 of which was unique. 
*Samples with null alleles (5) were not used in the analysis of this panel. 
+Site 3915 was not used for data analysis, as this site gave unusually low signal strength during the particular 
databasing run, and we haven’t yet resolved this presumably sporadic problem.  
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Figure 42.  Multiplex C applied to 276* Caucasian samples. 
The 11 multiplexed SNP sites of Multiplex C produced 18 SNP-types, 8 of which were unique. 
*Samples with partial profiles (8) were not used in the analysis of this panel. 
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Figure 43.  Multiplex E applied to 282* Caucasian samples. 
The 7 multiplexed SNP sites of Multiplex E produced 10 SNP-types, 3 of which were unique. 
*Samples with null alleles (2) were not used in the analysis of this panel. 
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Figure 44.  Multiplex F applied to 261* Caucasian samples. 
The 10 multiplexed SNP sites of Multiplex F produced 13 SNP-types, 6 of which were unique. 
*Samples with null alleles (23) were not used in the analysis of this panel. 
 
 
 
 
 
 
 
 
 
 
 
84 
This document is a research report submitted to the U.S. Department of Justice. This report has not 
been published by the Department. Opinions or points of view expressed are those of the author(s) 
and do not necessarily reflect the official position or policies of the U.S. Department of Justice.
 
 
 
Figure 45.  Multiplex G applied to 281* Caucasian samples. 
The 11 multiplexed SNP sites of Multiplex G produced 11 SNP-types, 5 of which were unique. 
*Samples with null alleles (3) were not used in the analysis of this panel. 
 
 
 
 
 
 
 
 
 
 
 
 
85 
This document is a research report submitted to the U.S. Department of Justice. This report has not 
been published by the Department. Opinions or points of view expressed are those of the author(s) 
and do not necessarily reflect the official position or policies of the U.S. Department of Justice.
 
 
 
Figure 46.  Multiplex H applied to 282* Caucasian samples. 
The 6 multiplexed SNP sites of Multiplex H produced 6 SNP-types, 1 of which was unique. 
*Samples with null alleles (2) were not used in the analysis of this panel. 
 
 
 
 
Tables 28-37 depict the breakdown of HV/SNP-types among HV-types that occurred 
more than once in the random Caucasian dataset.  An HV/SNP-type is defined here as the profile 
generated when HV sequence data and SNPs from a multiplex panel are taken together.  
Multiplex A discriminates well among the 17 samples matching HV-type H:1, resulting in six 
HV/SNP-types, four of which are unique (Table 28).  The results depicted in Table 28 also 
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indicate that Multiplex A discriminates well among samples that a match a near-H:1 type (here 
defined as an HV-type that differs from H:1 by only a single polymorphism), providing 
additional discrimination for three out of the four near-H:1 types duplicated in our dataset.  
Multiplex B, which targets additional haplogroup H HV-types, also performed well on the 
targeted and closely-related HV-types (Table 29).   
 
 
HV Type HV Profile Total Breakdown 
H:1 263G 315.1C  17 (8) (5) (1) (1) (1) (1)
H:1 + 16189 16189C 263G 315.1C 5 (3) (1) (1) 
H:1 + 16311 16311C 263G 315.1C 3 (1) (1) (1) 
H:1 + 16355 16355T 263G 315.1C  2 (2) 
H:1 + 93 93G 263G 315.1C 3 (1) (1) (1) 
H:2 152C 263G 315.1C 7 (4) (2) (1) 
H:3 16129A 263G 315.1C 3 (2) (1) 
H:5 16304C 263G 315.1C  6 (6) 
H:7 16162G 16209C 73G 263G 315.1C 5 (5) 
J:3 16069T 16126C 73G 185A 188G 228A 263G 295T 315.1C 2 (2) 
J:3 + 185 16069T 16126C 73G 146C 185A 188G 228A 263G 295T 315.1C  2 (2) 
K:1 16224C 16311C 73G 146C 152C 263G 315.1C 2 (2) 
K:3 + 195 16224C 16311C 73G 195C 263G 315.1C 2 (2) 
T:1 16126C 16294T 16296T 16304C 73G 263G 315.1C  2 (2) 
T:2 16126C 16163G 16186T 16189C 16294T 73G 152C 195C 263G 315.1C 4 (4) 
T:3 16126C 16294T 16296T 73G 263G 315.1C 3 (3) 
V:1 16298C 263G 315.1C 3 (2) (1) 
- 16069T 16126C 16145A 16231C 16261T 73G 150T 152C 195C 215G 263G 295T 310.1T 315.1C 319C  6 (5) (1) 
- 16126C 16172C 16266T 16292T 16294T 73G 152C 263G 315.1C  2 (4) 
- 16126C 16187T 16294T 16296T 16304C 73G 151T 263G 315.1C 2 (2) 
- 16147A 16154C 16172C 16223T 16248T 16320T 16355T 73G 152C 199C 204C 263G 315.1C  2 (2) 
- 16256T 16270T 73G 263G 315.1C 4 (2) 
- 16293G 16311C 195C 263G 315.1C 2 (1) (1) 
- 16294T 16304C 198T 263G 315.1C  2 (2) 
- 16362C 239C 263G 315.1C 2 (2) 
  93 1 null allele* 
Table 28.  Breakdown of 93* non-unique HV-type samples by Multiplex A.   
The application of Multiplex A to 25 non-unique HV-types resulted in 42 different HV/SNP-types 
including 18 unique types.  This panel targets the H:1 HV-type, highlighted in yellow. 
*One sample with a null allele was not included for data analysis.  
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 HV Type HV Profile Total Breakdown 
H:1 263G 315.1C  17 (6) (5) (2) (1) (1) (1) (1) 
H:1 + 16189 16189C 263G 315.1C 6 (4) (1) (1) 
H:1 + 16311 16311C 263G 315.1C 3 (2) (1) 
H:1 + 16355 16355T 263G 315.1C  2 (2) 
H:1 + 93 93G 263G 315.1C 3 (1) (1) (1) 
H:2 152C 263G 315.1C 7 (2) (2) (1) (1) (1) 
H:3 16129A 263G 315.1C 3 (1) (1) (1) 
H:5 16304C 263G 315.1C  6 (6) 
H:7 16162G 16209C 73G 263G 315.1C 5 (5) 
J:3 16069T 16126C 73G 185A 188G 228A 263G 295T 315.1C 2 (2) 
J:3 + 185 16069T 16126C 73G 146C 185A 188G 228A 263G 295T 315.1C  2 (2) 
K:1 16224C 16311C 73G 146C 152C 263G 315.1C 2 (2) 
K:3 + 195 16224C 16311C 73G 195C 263G 315.1C 2 (2) 
T:1 16126C 16294T 16296T 16304C 73G 263G 315.1C  2 (2) 
T:2 16126C 16163G 16186T 16189C 16294T 73G 152C 195C 263G 315.1C 4 (4) 
T:3 16126C 16294T 16296T 73G 263G 315.1C 3 (3) 
V:1 16298C 263G 315.1C 3 (2) (1) 
- 16069T 16126C 16145A 16231C 16261T 73G 150T 152C 195C 215G 263G 295T 310.1T 315.1C 319C  6 (5) (1) 
- 16126C 16172C 16266T 16292T 16294T 73G 152C 263G 315.1C  2 (2) 
- 16126C 16187T 16294T 16296T 16304C 73G 151T 263G 315.1C 2 (2) 
- 16147A 16154C 16172C 16223T 16248T 16320T 16355T 73G 152C 199C 204C 263G 315.1C  2 (2) 
- 16256T 16270T 73G 263G 315.1C 4 (4) 
- 16293G 16311C 195C 263G 315.1C 2 (1) (1) 
- 16294T 16304C 198T 263G 315.1C  2 (2) 
- 16362C 239C 263G 315.1C 2 (2) 
Also targets 
H:6 HV type  94  
 
Table 29.  Breakdown of 94 non-unique HV-type samples by Multiplex B. 
The application of Multiplex B to 25 non-unique HV-types resulted in 45 different HV/SNP-types 
including 20 unique types.  This panel targets H:2 and H:3 HV-types, highlighted in yellow. 
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 HV Type V Profile Total Breakdown 
H:1 263G 315.1C  16 (13) (2) (1) 
H:1 + 16189 16189C 263G 315.1C 6 (5) (1) 
H:1 + 16311 16311C 263G 315.1C 3 (2) (1) 
H:1 + 16355 16355T 263G 315.1C  2 (2) 
H:1 + 93 93G 263G 315.1C 3 (2) (1) 
H:2 152C 263G 315.1C 7 (6) (1) 
H:3 16129A 263G 315.1C 3 (2) (1) 
H:5 16304C 263G 315.1C  5 (3) (2) 
H:7 16162G 16209C 73G 263G 315.1C 5 (5) 
J:3 16069T 16126C 73G 185A 188G 228A 263G 295T 315.1C 2 (2) 
J:3 + 185 16069T 16126C 73G 146C 185A 188G 228A 263G 295T 315.1C  2 (2) 
K:1 16224C 16311C 73G 146C 152C 263G 315.1C 2 (2) 
K:3 + 195 16224C 16311C 73G 195C 263G 315.1C 2 (1) (1) 
T:1 16126C 16294T 16296T 16304C 73G 263G 315.1C  2 (2) 
T:2 16126C 16163G 16186T 16189C 16294T 73G 152C 195C 263G 315.1C 4 (4) 
T:3 16126C 16294T 16296T 73G 263G 315.1C 3 (3) 
V:1 16298C 263G 315.1C 3 (2) (1) 
- 16069T 16126C 16145A 16231C 16261T 73G 150T 152C 195C 215G 263G 295T 310.1T 315.1C 319C  6 (5) (1) 
- 16126C 16172C 16266T 16292T 16294T 73G 152C 263G 315.1C  2 (2) 
- 16126C 16187T 16294T 16296T 16304C 73G 151T 263G 315.1C 2 (2) 
- 16147A 16154C 16172C 16223T 16248T 16320T 16355T 73G 152C 199C 204C 263G 315.1C  2 (2) 
- 16256T 16270T 73G 263G 315.1C 4 (4) 
- 16293G 16311C 195C 263G 315.1C 2 (1) (1) 
- 16294T 16304C 198T 263G 315.1C  2 (2) 
- 16362C 239C 263G 315.1C 2 (2) 
  92 2 partial profiles* 
 
 
Table 30.  Breakdown of 92* non-unique HV-type samples by Multiplex C. 
The application of Multiplex C to 25 non-unique HV-types resulted in 37 different HV/SNP-types 
including 12 unique types.  This panel targets H:5 and V:1 HV-types, highlighted in yellow. 
*Samples with partial profiles (2) were not included for data analysis. 
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HV Type HV Profile Total Breakdown 
H:1 263G 315.1C  17 (15) (2) 
H:1 + 16189 16189C 263G 315.1C 6 (5) (1) 
H:1 + 16311 16311C 263G 315.1C 3 (2) (1) 
H:1 + 16355 16355T 263G 315.1C  2 (2) 
H:1 + 93 93G 263G 315.1C 3 (2) (1) 
H:2 152C 263G 315.1C 7 (6) (1) 
H:3 16129A 263G 315.1C 3 (2) (1) 
H:5 16304C 263G 315.1C  6 (6) 
H:7 16162G 16209C 73G 263G 315.1C 5 (4) (1) 
J:3 16069T 16126C 73G 185A 188G 228A 263G 295T 315.1C 2 (2) 
J:3 + 185 16069T 16126C 73G 146C 185A 188G 228A 263G 295T 315.1C  2 (2) 
K:1 16224C 16311C 73G 146C 152C 263G 315.1C 2 (2) 
K:3 + 195 16224C 16311C 73G 195C 263G 315.1C 2 (2) 
T:1 16126C 16294T 16296T 16304C 73G 263G 315.1C  2 (2) 
T:2 16126C 16163G 16186T 16189C 16294T 73G 152C 195C 263G 315.1C 4 (4) 
T:3 16126C 16294T 16296T 73G 263G 315.1C 3 (3) 
V:1 16298C 263G 315.1C 3 (2) (1) 
- 16069T 16126C 16145A 16231C 16261T 73G 150T 152C 195C 215G 263G 295T 310.1T 315.1C 319C  6 (5) (1) 
- 16126C 16172C 16266T 16292T 16294T 73G 152C 263G 315.1C  2 (2) 
- 16126C 16187T 16294T 16296T 16304C 73G 151T 263G 315.1C 2 (2) 
- 16147A 16154C 16172C 16223T 16248T 16320T 16355T 73G 152C 199C 204C 263G 315.1C  2 (2) 
- 16256T 16270T 73G 263G 315.1C 4 (4) 
- 16293G 16311C 195C 263G 315.1C 2 (1) (1) 
- 16294T 16304C 198T 263G 315.1C  2 (2) 
- 16362C 239C 263G 315.1C 2 (2) 
Also targets 
H:4 and J:4 
HV types 
 94  
 
Table 31.  Breakdown of 94 non-unique HV-type samples by Multiplex E. 
The application of Multiplex E to 25 non-unique HV-types resulted in 35 different HV/SNP-types 
including 10 unique types.  This panel targets H:4, J:4, T:2, and T:3 HV-types, highlighted in yellow. 
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HV Type HV Profile Total Breakdown 
H:1 263G 315.1C  17 (15) (1) (1) 
H:1 + 16189 16189C 263G 315.1C 6 (6) 
H:1 + 16311 16311C 263G 315.1C 3 (3) 
H:1 + 16355 16355T 263G 315.1C  2 (2) 
H:1 + 93 93G 263G 315.1C 3 (3) 
H:2 152C 263G 315.1C 7 (6) (1) 
H:3 16129A 263G 315.1C 3 (1) (1) (1) 
H:5 16304C 263G 315.1C  6 (6) 
H:7 16162G 16209C 73G 263G 315.1C 5 (5) 
J:3 16069T 16126C 73G 185A 188G 228A 263G 295T 315.1C 2 (2) 
J:3 + 185 16069T 16126C 73G 146C 185A 188G 228A 263G 295T 315.1C  2 (2) 
K:1 16224C 16311C 73G 146C 152C 263G 315.1C 2 (2) 
K:3 + 195 16224C 16311C 73G 195C 263G 315.1C 2 (2) 
T:1 16126C 16294T 16296T 16304C 73G 263G 315.1C  1 (1) 
T:2 16126C 16163G 16186T 16189C 16294T 73G 152C 195C 263G 315.1C 2 (2) 
T:3 16126C 16294T 16296T 73G 263G 315.1C 1 (1) 
V:1 16298C 263G 315.1C 3 (3) 
- 16069T 16126C 16145A 16231C 16261T 73G 150T 152C 195C 215G 263G 295T 310.1T 315.1C 319C  6 (6) 
- 16126C 16172C 16266T 16292T 16294T 73G 152C 263G 315.1C  1 (1) 
- 16126C 16187T 16294T 16296T 16304C 73G 151T 263G 315.1C 1 (1) 
- 16147A 16154C 16172C 16223T 16248T 16320T 16355T 73G 152C 199C 204C 263G 315.1C  2 (2) 
- 16256T 16270T 73G 263G 315.1C 4 (4) 
- 16293G 16311C 195C 263G 315.1C 2 (2) 
- 16294T 16304C 198T 263G 315.1C  2 (2) 
- 16362C 239C 263G 315.1C 2 (2) 
    87 7 null alleles* 
 
Table 32.  Breakdown of 87* non-unique HV-type samples by Multiplex F. 
The application of Multiplex F to 21 non-unique HV-types resulted in 26 different HV/SNP-types 
including 6 unique types.  This panel provides additional discrimination for H:1, H:2, H:3, and V:1 HV-
types, highlighted in light yellow. 
*Samples with null alleles (7) were not included for data analysis. 
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HV Type HV Profile Total Breakdown 
H:1 263G 315.1C  17 (14) (2) (1) 
H:1 + 16189 16189C 263G 315.1C 6 (6) 
H:1 + 16311 16311C 263G 315.1C 3 (2) (1) 
H:1 + 16355 16355T 263G 315.1C  2 (2) 
H:1 + 93 93G 263G 315.1C 3 (2) (1) 
H:2 152C 263G 315.1C 7 (6) (1) 
H:3 16129A 263G 315.1C 3 (2) (1) 
H:5 16304C 263G 315.1C  6 (6) 
H:7 16162G 16209C 73G 263G 315.1C 5 (5) 
J:3 16069T 16126C 73G 185A 188G 228A 263G 295T 315.1C 2 (2) 
J:3 + 185 16069T 16126C 73G 146C 185A 188G 228A 263G 295T 315.1C  2 (2) 
K:1 16224C 16311C 73G 146C 152C 263G 315.1C 2 (2) 
K:3 + 195 16224C 16311C 73G 195C 263G 315.1C 2 (1) (1) 
T:1 16126C 16294T 16296T 16304C 73G 263G 315.1C  2 (2) 
T:2 16126C 16163G 16186T 16189C 16294T 73G 152C 195C 263G 315.1C 4 (4) 
T:3 16126C 16294T 16296T 73G 263G 315.1C 3 (3) 
V:1 16298C 263G 315.1C 3 (2) (1) 
- 16069T 16126C 16145A 16231C 16261T 73G 150T 152C 195C 215G 263G 295T 310.1T 315.1C 319C  6 (5) (1) 
- 16126C 16172C 16266T 16292T 16294T 73G 152C 263G 315.1C  2 (2) 
- 16126C 16187T 16294T 16296T 16304C 73G 151T 263G 315.1C 2 (2) 
- 16147A 16154C 16172C 16223T 16248T 16320T 16355T 73G 152C 199C 204C 263G 315.1C  2 (2) 
- 16256T 16270T 73G 263G 315.1C 4 (4) 
- 16293G 16311C 195C 263G 315.1C 2 (1) (1) 
- 16294T 16304C 198T 263G 315.1C  2 (2) 
- 16362C 239C 263G 315.1C 2 (2) 
Also targets 
J:1 HV type  94  
 
Table 33.  Breakdown of 94 non-unique HV-type samples by Multiplex G. 
The application of Multiplex G to 25 non-unique HV-types resulted in 35 different HV/SNP-types 
including 11 unique types.  This panel targets J:1, J:3, and T:1 HV-types, highlighted in yellow. 
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HV Type HV Profile Total Breakdown 
H:1 263G 315.1C  17 (15) (2) 
H:1 + 16189 16189C 263G 315.1C 6 (6) 
H:1 + 16311 16311C 263G 315.1C 3 (2) (1) 
H:1 + 16355 16355T 263G 315.1C  2 (2) 
H:1 + 93 93G 263G 315.1C 3 (2) (1) 
H:2 152C 263G 315.1C 7 (6) (1) 
H:3 16129A 263G 315.1C 3 (2) (1) 
H:5 16304C 263G 315.1C  6 (6) 
H:7 16162G 16209C 73G 263G 315.1C 5 (5) 
J:3 16069T 16126C 73G 185A 188G 228A 263G 295T 315.1C 2 (2) 
J:3 + 185 16069T 16126C 73G 146C 185A 188G 228A 263G 295T 315.1C  2 (2) 
K:1 16224C 16311C 73G 146C 152C 263G 315.1C 2 (1) (1) 
K:3 + 195 16224C 16311C 73G 195C 263G 315.1C 2 (2) 
T:1 16126C 16294T 16296T 16304C 73G 263G 315.1C  2 (2) 
T:2 16126C 16163G 16186T 16189C 16294T 73G 152C 195C 263G 315.1C 4 (4) 
T:3 16126C 16294T 16296T 73G 263G 315.1C 3 (3) 
V:1 16298C 263G 315.1C 3 (2) (1) 
- 16069T 16126C 16145A 16231C 16261T 73G 150T 152C 195C 215G 263G 295T 310.1T 315.1C 319C  6 (5) (1) 
- 16126C 16172C 16266T 16292T 16294T 73G 152C 263G 315.1C  2 (2) 
- 16126C 16187T 16294T 16296T 16304C 73G 151T 263G 315.1C 2 (2) 
- 16147A 16154C 16172C 16223T 16248T 16320T 16355T 73G 152C 199C 204C 263G 315.1C  2 (2) 
- 16256T 16270T 73G 263G 315.1C 4 (4) 
- 16293G 16311C 195C 263G 315.1C 2 (1) (1) 
- 16294T 16304C 198T 263G 315.1C  2 (2) 
- 16362C 239C 263G 315.1C 2 (2) 
  94  
 
Table 34.  Breakdown of 94 non-unique HV-type samples by Multiplex H. 
The application of Multiplex H to 25 non-unique HV-types resulted in 34 different HV/SNP-types 
including 10 unique types.  This panel targets the K:1 HV-type, highlighted in yellow. 
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HV Type HV Profile Total Breakdown 
H:1 263G 315.1C  17 (7) (4) (1) (1) (1) (1) (1) (1) 
H:1 + 16189 16189C 263G 315.1C 5 (3) (1) (1) 
H:1 + 16311 16311C 263G 315.1C 3 (1) (1) (1) 
H:1 + 16355 16355T 263G 315.1C  2 (2) 
H:1 + 93 93G 263G 315.1C 3 (1) (1) (1) 
H:2 152C 263G 315.1C 7 (3) (2) (1) (1) 
H:3 16129A 263G 315.1C 3 (1) (1) (1) 
H:5 16304C 263G 315.1C  6 (6) 
H:7 16162G 16209C 73G 263G 315.1C 5 (5) 
J:3 16069T 16126C 73G 185A 188G 228A 263G 295T 315.1C 2 (2) 
J:3 + 185 16069T 16126C 73G 146C 185A 188G 228A 263G 295T 315.1C  2 (2) 
K:1 16224C 16311C 73G 146C 152C 263G 315.1C 2 (2) 
K:3 + 195 16224C 16311C 73G 195C 263G 315.1C 2 (2) 
T:1 16126C 16294T 16296T 16304C 73G 263G 315.1C  1 (1) 
T:2 16126C 16163G 16186T 16189C 16294T 73G 152C 195C 263G 315.1C 2 (2) 
T:3 16126C 16294T 16296T 73G 263G 315.1C 1 (1) 
V:1 16298C 263G 315.1C 3 (2) (1) 
- 16069T 16126C 16145A 16231C 16261T 73G 150T 152C 195C 215G 263G 295T 310.1T 315.1C 319C  6 (5) (1) 
- 16126C 16172C 16266T 16292T 16294T 73G 152C 263G 315.1C  1 (1) 
- 16126C 16187T 16294T 16296T 16304C 73G 151T 263G 315.1C 1 (1) 
- 16147A 16154C 16172C 16223T 16248T 16320T 16355T 73G 152C 199C 204C 263G 315.1C  2 (2) 
- 16256T 16270T 73G 263G 315.1C 4 (4) 
- 16293G 16311C 195C 263G 315.1C 2 (1) (1) 
- 16294T 16304C 198T 263G 315.1C  2 (2) 
- 16362C 239C 263G 315.1C 2 (2) 
  86 8 null alleles* 
 
 
Table 35.  Breakdown of 86 non-unique HV-type samples by Multiplexes A and F. 
The application of Multiplexes A and F to 21 non-unique HV-types resulted in 42 different HV/SNP-
types including 23 unique types.  Multiplexes A and F are the primary and secondary multiplexes for HV-
type H:1, highlighted in orange. 
*Samples with null alleles (8) were not included for data analysis. 
 
 
 
 
 
 
 
 
 
 
 
94 
This document is a research report submitted to the U.S. Department of Justice. This report has not 
been published by the Department. Opinions or points of view expressed are those of the author(s) 
and do not necessarily reflect the official position or policies of the U.S. Department of Justice.
HV Type HV Profile Total Breakdown 
H:1 263G 315.1C  17 (6) (4) (2) (1) (1) (1) (1) (1) 
H:1 + 16189 16189C 263G 315.1C 6 (4) (1) (1) 
H:1 + 16311 16311C 263G 315.1C 3 (2) (1) 
H:1 + 16355 16355T 263G 315.1C  2 (2) 
H:1 + 93 93G 263G 315.1C 3 (1) (1) (1) 
H:2 152C 263G 315.1C 7 (2) (2) (1) (1) (1) 
H:3 16129A 263G 315.1C 3 (1) (1) (1) 
H:5 16304C 263G 315.1C  6 (6) 
H:7 16162G 16209C 73G 263G 315.1C 5 (5) 
J:3 16069T 16126C 73G 185A 188G 228A 263G 295T 315.1C 2 (2) 
J:3 + 185 16069T 16126C 73G 146C 185A 188G 228A 263G 295T 315.1C  2 (2) 
K:1 16224C 16311C 73G 146C 152C 263G 315.1C 2 (2) 
K:3 + 195 16224C 16311C 73G 195C 263G 315.1C 2 (2) 
T:1 16126C 16294T 16296T 16304C 73G 263G 315.1C  1 (1) 
T:2 16126C 16163G 16186T 16189C 16294T 73G 152C 195C 263G 315.1C 2 (2) 
T:3 16126C 16294T 16296T 73G 263G 315.1C 1 (1) 
V:1 16298C 263G 315.1C 3 (2) (1) 
- 16069T 16126C 16145A 16231C 16261T 73G 150T 152C 195C 215G 263G 295T 310.1T 315.1C 319C  6 (5) (1) 
- 16126C 16172C 16266T 16292T 16294T 73G 152C 263G 315.1C  1 (1) 
- 16126C 16187T 16294T 16296T 16304C 73G 151T 263G 315.1C 1 (1) 
- 16147A 16154C 16172C 16223T 16248T 16320T 16355T 73G 152C 199C 204C 263G 315.1C  2 (2) 
- 16256T 16270T 73G 263G 315.1C 3 (3) 
- 16293G 16311C 195C 263G 315.1C 2 (1) (1) 
- 16294T 16304C 198T 263G 315.1C  2 (2) 
- 16362C 239C 263G 315.1C 2 (2) 
  86 8 null alleles* 
 
 
Table 36.  Breakdown of 86 non-unique HV-type samples by Multiplexes B and F. 
The application of Multiplexes B and F to 21 non-unique HV-types resulted in 42 different HV/SNP-
types including 21 unique types.  Multiplexes B and F are the primary and secondary multiplexes for HV-
types H:2 and H:3, highlighted in orange. 
*Samples with null alleles (8) were not included for data analysis. 
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HV Type HV Profile Total Breakdown 
H:1 263G 315.1C  16 (11) (2) (1) (1) (1) 
16189C 263G 315.1C 6 (5) (1) 
H:1 + 16311 16311C 263G 315.1C 3 (2) (1) 
H:1 + 16355 16355T 263G 315.1C  2 (2) 
H:1 + 93 93G 263G 315.1C 3 (2) (1) 
H:2 152C 263G 315.1C 7 (5) (1) (1) 
H:3 16129A 263G 315.1C 3 (1) (1) (1) 
H:5 16304C 263G 315.1C  5 (3) (2) 
H:7 16162G 16209C 73G 263G 315.1C 5 (5) 
J:3 16069T 16126C 73G 185A 188G 228A 263G 295T 315.1C 2 (2) 
J:3 + 185 16069T 16126C 73G 146C 185A 188G 228A 263G 295T 315.1C  2 (2) 
K:1 16224C 16311C 73G 146C 152C 263G 315.1C 2 (2) 
K:3 + 195 16224C 16311C 73G 195C 263G 315.1C 2 (1) (1) 
T:1 16126C 16294T 16296T 16304C 73G 263G 315.1C  1 (1) 
T:2 16126C 16163G 16186T 16189C 16294T 73G 152C 195C 263G 315.1C 2 (2) 
T:3 16126C 16294T 16296T 73G 263G 315.1C 1 (1) 
V:1 16298C 263G 315.1C 3 (2) (1) 
- 16069T 16126C 16145A 16231C 16261T 73G 150T 152C 195C 215G 263G 295T 310.1T 315.1C 319C  6 (5) (1) 
- 16126C 16172C 16266T 16292T 16294T 73G 152C 263G 315.1C  1 (1) 
- 16126C 16187T 16294T 16296T 16304C 73G 151T 263G 315.1C 1 (1) 
- 16147A 16154C 16172C 16223T 16248T 16320T 16355T 73G 152C 199C 204C 263G 315.1C  2 (2) 
- 16256T 16270T 73G 263G 315.1C 4 (4) 
- 16293G 16311C 195C 263G 315.1C 2 (1) (1) 
- 16294T 16304C 198T 263G 315.1C  2 (2) 
- 16362C 239C 263G 315.1C 2 (2) 
  85 9 not included* 
H:1 + 16189 
 
Table 37:  Breakdown of 86 non-unique HV-type samples by Multiplexes C and F. 
The application of Multiplexes C and F to 21 non-unique HV-types resulted in 37 different HV/SNP-
types including 17 unique types.  Multiplexes C and F are the primary and secondary multiplexes for HV-
type V:1, highlighted in orange. 
*Samples with null alleles (7) or partial profiles (2) were not included for data analysis. 
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Conclusions and Future Directions 
 
 Accomplishing the goals of this project has resulted in the development of a refined 
automated system, relying on robotics and bioinformatics, for high throughput mtDNA 
sequencing [we note that infrastructure, instrumentation, and software development costs were 
independent of NIJ funding].  In order to identify samples matching common HV types for entire 
mtGenome sequencing, new databases of entire control region sequences were established for an 
African American sample, and four regional Hispanic databases.  Significant differences in 
haplogroup and haplotype representation among the regional Hispanic databases suggests that 
additional attention should be paid to the issue of population subdivision, especially involving 
inherently heterogeneous population categories such as “Hispanics.” 
This work represents the first comprehensive demonstration that variation in the mtDNA 
coding region can provide substantial levels forensic discrimination, over and above the variation 
present in the hypervariable regions of the control region.  Admittedly, knowledge of relative 
rates of sequence evolution in the control region versus the coding region, and their relative size, 
made that a bit of a foregone conclusion.  However, what was very much an open question at the 
outset of this project was whether the additional variation was distributed in such a manner that it 
could be practically accessed within the context of real-world forensic mtDNA testing.  It is 
clearly—for the immediately foreseeable future—unrealistic to sequence the entire mtDNA 
genome for mtDNA casework samples.  Normally, retrieving sequence from the control region 
leaves only a small amount of evidentiary extract left, so that only small portions of the coding 
region could be expected to be recovered.  As a result of this project, we moreover know that the 
distribution of variation in the coding region is such that sequencing any practically attainable 
number of small fragments, using the same general approach for any case in question, will rarely 
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provide additional forensic discrimination (this is presented in detail in Coble et al., 2005).  
Using high-throughput mtGenome sequencing of common HV types, we have identified SNP 
sites that are highly useful for providing additional discrimination for those HV-types (and their 
near relatives) that will most often be involved in cases where additional discrimination is 
needed.  This approach was particularly useful in the case of common HV types in the US 
Caucasian population.  Smaller available sample sizes for whole mtGenome sequencing 
somewhat limited the ability to identify a large number of discriminatory sites in African 
American and Hispanic common HV types;  and in some Hispanic types we simply observed 
low levels of variation (a limitation for any approach).  Nonetheless, for all population groups 
studied, useful SNP panels were identified. For Caucasians, multiplex ASPE assays were 
designed, optimized, and demonstrated to work effectively on degraded samples. 
Based on the results reported from this project, the primary use of the SNP panels is to 
distinguish among multiple matching samples, refining inclusion and exclusion from within a 
closed set of compared sequences.  An alternative desirable application would be to simply 
increase the evidentiary significance of a single match involving one of the common types.  For 
example, instead of an HV type that matches 7% of the population, combining SNP data might 
result in a SNP/HV type present in 0.5% of the population, increasing the significance of the 
match.  However, for this purpose, large population databases that combine SNPs and HV 
sequences are necessary.   AFDIL is presently planning to add SNP panel typing to current 
family reference databasing, which will quickly increase to large numbers, and will make that 
data available as the project is implemented.  In this case, it would be only be necessary to apply 
the SNP panels to those population samples for which they are relevant.  However, in addition to 
having the databases available, wide use of this approach will also require labs to have access to 
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population search engines that accommodate the SNP data (AFDIL’s LIMS system already 
incorporates this, but there are no current plans for the search function to be openly available).  
As the field progresses toward use of discriminatory SNPs, modifications to the publicly 
available searchable databases such as CODISmt and EMPOP would be highly desirable.   
 This project is undoubtedly only the beginning of identifying methods for obtaining data 
ranging over the entire mtDNA genome, to powerfully increase forensic discrimination.  The 
ASPE assays we designed give forensic laboratories this ability, now, for many of the 
circumstances where need will arise.  However, the implementation of the ASPE assay, while 
simple in practice, carries a high burden of effort regarding primer quality control, and we 
suspect this will be a limitation to very widespread adoption of this technique.  The field of 
forensic DNA analysis is aggressively developing new SNP typing methods, and maximum 
benefit to the field would be in commercial availability of a (fast, cheap, and easy) SNP typing 
kit, where primary QC issues are removed from individual laboratory.  Fortunately, interest has 
been expressed by a number of companies in this regard.  We note that, with DNA sequencing 
becoming ever less expensive and time consuming, that it may be feasible to sequences the entire 
mtGenome from reference samples, in the not-distant future.  This could then direct the 
investigation of degraded evidentiary samples to particular portions of the mtGenome that could 
be targeted for a high probability of excluding unrelated individuals.  In any case, the primary 
mtGenome data generated for this study will be a highly useful reference for guiding the 
development of new approaches. 
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Appendix I: Control Region Amplification and Sequencing Primer Sequences 
 
Primer Type Sequence Notes 
F15971 Amp TTAACTCCACCATTAGCACC also used for sequencing 
R599 Amp TTGAGGAGGTAAGCTACATA also used for sequencing 
F16190 Sequencing CCCCATGCTTACAAGCAAGT   
F16450 Sequencing GCTCCGGGCCCATAACACTTG   
F34 Sequencing GGGAGCTCTCCATGCATTTGGTA   
F314 Sequencing CCGCTTCTGGCCACAGCACT   
R285 Sequencing GTTATGATGTCTGTGTGGAA   
R16400 Sequencing GTCAAGGGACCCCTATCTGA   
F15971 Sequencing TTAACTCCACCATTAGCACC   
R599 Sequencing TTGAGGAGGTAAGCTACATA   
 
 
 
 
 
Appendix II: Entire mtDNA Genome Amplification and Sequencing Primer Sequences 
 
Amp Primer Type Sequence Notes 
1 F361 Amp ACAAAGAACCCTAACACCAGC also used for sequencing 
1 R2216 Amp TGTTGAGCTTGAACGCTTTC also used for sequencing 
2 F1993 Amp AAACCTACCGAGCCTGGTG also used for sequencing 
2 R3557 Amp AGAAGAGCGATGGTGAGAGC also used for sequencing 
3 F3441 Amp ACTACAACCCTTCGCTGACG also used for sequencing 
3 R4982 Amp GTTTAATCCACCTCAACTGCC also used for sequencing 
4 F4797 Amp CCCTTTCACTTCTGAGTCCCAG also used for sequencing 
4 R6526 Amp ATAGTGATGCCAGCAGCTAGG also used for sequencing 
5 F6426 Amp GCCATAACCCAATACCAAACG also used for sequencing 
5 R8311 Amp AAGTTAGCTTTACAGTGGGCTCTAG also used for sequencing 
6 F8164 Amp CGGTCAATGCTCTGAAATCTGTG also used for sequencing 
6 R9848 Amp GAAAGTTGAGCCAATAATGACG also used for sequencing 
7 F9754 Amp AGTCTCCCTTCACCATTTCCG also used for sequencing 
7 R11600 Amp CTGTTTGTCGTAGGCAGATGG also used for sequencing 
8 F11403 Amp GACTCCCTAAAGCCCATGTCG also used for sequencing 
8 R13123 Amp AGCGGATGAGTAAGAAGATTCC also used for sequencing 
9 F12793 Amp TTGCTCATCAGTTGATGATACG also used for sequencing 
9 R14388 Amp TTAGCGATGGAGGTAGGATTGG also used for sequencing 
10 F14189 Amp ACAAACAATGGTCAACCAGTAAC also used for sequencing 
10 R15396 Amp TTATCGGAATGGGAGGTGATTC also used for sequencing 
11 F15260 Amp AGTCCCACCCTCACACGATTC also used for sequencing 
11 R16084 Amp CGGTTGTTGATGGGTGAGTC also used for sequencing 
12 F15878 Amp AAATGGGCCTGTCCTTGTAG also used for sequencing 
12 R649 Amp TTTGTTTATGGGGTGATGTGA also used for sequencing 
1 F361 Sequencing ACAAAGAACCCTAACACCAGC also used for amplification 
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1 F1234 Sequencing CTCACCACCTCTTGCTCAGC   
1 F1657 Sequencing CTTGACCGCTCTGAGCTAAAC   
1 F756 Sequencing CATCAAGCACGCAGCAATG   
1 F873 Sequencing GGTTGGTCAATTTCGTGCCAG   
1 R1425 Sequencing AATCCACCTTCGACCCTTAAG   
1 R1769 Sequencing GCCAGGTTTCAATTTCTATCG   
1 R2216 Sequencing TGTTGAGCTTGAACGCTTTC also used for amplification 
1 R921 Sequencing ACTTGGGTTAATCGTGTGACC   
2 F1993 Sequencing AAACCTACCGAGCCTGGTG also used for amplification 
2 F2105 Sequencing GAGGAACAGCTCTTTGGACAC   
2 F2417 Sequencing CACTGTCAACCCAACACAGG   
2 F2834 Sequencing CCCAACCTCCGAGCAGTACATG   
2 F3234 Sequencing AGATGGCAGAGCCCGGTAATC   
2 R2660 Sequencing AGAGACAGCTGAACCCTCGTG   
2 R3006 Sequencing ATGTCCTGATCCAACATCGAG   
2 R3557 Sequencing AGAAGAGCGATGGTGAGAGC also used for amplification 
3 F3441 Sequencing ACTACAACCCTTCGCTGACG also used for amplification 
3 F3931 Sequencing TCAGGCTTCAACATCGAATACG   
3 F4392 Sequencing CCCATCCTAAAGTAAGGTCAGC   
3 R3940 Sequencing TGAAGCCTGAGACTAGTTCGG   
3 R4162 Sequencing TGAGTTGGTCGTAGCGGAATC   
3 R4982 Sequencing GTTTAATCCACCTCAACTGCC also used for amplification 
4 F4797 Sequencing CCCTTTCACTTCTGAGTCCCAG also used for amplification 
4 F5318 Sequencing CACCATCACCCTCCTTAACC   
4 F5700 Sequencing TAAGCACCCTAATCAACTGGC   
4 F6242 Sequencing CGCATCTGCTATAGTGGAGG   
4 R5882 Sequencing GCTGAGTGAAGCATTGGACTG   
4 R6526 Sequencing ATAGTGATGCCAGCAGCTAGG also used for amplification 
5 F6426 Sequencing GCCATAACCCAATACCAAACG also used for amplification 
5 F7075 Sequencing GAGGCTTCATTCACTGATTTCC   
5 F7645 Sequencing TATCACCTTTCATGATCACGC   
5 R7255 Sequencing TTTCATGTGGTGTATGCATCG   
5 R7792 Sequencing GGGCAGGATAGTTCAGACGG   
5 R8311 Sequencing AAGTTAGCTTTACAGTGGGCTCTAG also used for amplification 
6 F8164 Sequencing CGGTCAATGCTCTGAAATCTGTG also used for amplification 
6 F8539 Sequencing CTGTTCGCTTCATTCATTGCC   
6 F8903 Sequencing CCCACTTCTTACCACAAGGC   
6 F9309 Sequencing TTTCACTTCCACTCCATAACGC   
6 R9059 Sequencing GTGGCGCTTCCAATTAGGTG   
6 R9403 Sequencing GTGCTTTCTCGTGTTACATCG   
6 R9848 Sequencing GAAAGTTGAGCCAATAATGACG also used for amplification 
7 F10127 Sequencing ACTACCACAACTCAACGGCTAC   
7 F10386 Sequencing GGATTAGACTGAACCGAATTGG   
7 F11001 Sequencing AACGCCACTTATCCAGTGAACC   
7 F9754 Sequencing AGTCTCCCTTCACCATTTCCG also used for amplification 
7 R10275 Sequencing AAAGGAGGGCAATTTCTAGATC   
7 R10556 Sequencing GGAGGATATGAGGTGTGAGGG   
7 R11166 Sequencing CATCGGGTGATGATAGCCAAG   
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7 R11267 Sequencing TGTTGTGAGTGTAAATTAGTGCG   
7 R11600 Sequencing CTGTTTGTCGTAGGCAGATGG also used for amplification 
8 F11403 Sequencing GACTCCCTAAAGCCCATGTCG also used for amplification 
8 F11908 Sequencing AACCACGTTCTCCTGATCAAA   
8 F12357 Sequencing AACCACCCTAACCCTGACTTCC   
8 F12601 Sequencing TTCATCCCTGTAGCATTGTTCG   
8 R12876 Sequencing GATATCGCCGATACGGTTG   
8 R13123 Sequencing AGCGGATGAGTAAGAAGATTCC also used for amplification 
9 F12793 Sequencing TTGCTCATCAGTTGATGATACG also used for amplification 
9 F13188 Sequencing CACTCTGTTCGCAGCAGTATG   
9 F13518 Sequencing CATCATCGAAACCGCAAAC   
9 F13899 Sequencing TTTCTCCAACATACTCGGATTC   
9 R13343 Sequencing TTGAAGAAGGCGTGGGTACAG   
9 Sequencing TCGAGTGCTATAGGCGCTTGTC   
Sequencing TGTGATGCTAGGGTAGAATCCG 
10 F14189 Sequencing ACAAACAATGGTCAACCAGTAAC also used for amplification 
10 Sequencing TCCAAAGACAACCATCATTCC   
10 F14909 Sequencing TACTCACCAGACGCCTCAACCG   
10 R14996 Sequencing CGTGAAGGTAGCGGATGATTC   
10 R15396 Sequencing TTATCGGAATGGGAGGTGATTC also used for amplification 
11 F15260 Sequencing AGTCCCACCCTCACACGATTC 
11 F15574 Sequencing CGCCTACACAATTCTCCGATC   
11 Sequencing ACTGGTTGTCCTCCGATTCAGG   
11 R16084 Sequencing CGGTTGTTGATGGGTGAGTC 
12 F15878 Sequencing AAATGGGCCTGTCCTTGTAG also used for amplification 
12 Sequencing CCCCATGCTTACAAGCAAGT   
12 F16450 Sequencing GCTCCGGGCCCATAACACTTG 
12 F314 Sequencing CCGCTTCTGGCCACAGCACT   
12 Sequencing TGGATTGGGTTTTTATGTA   
12 R16400 Sequencing GTCAAGGGACCCCTATCTGA   
12 R285 Sequencing GTTATGATGTCTGTGTG AA   
12 R649 Sequencing TTTGTTTATGGGGTGATGTGA also used for amplification 
1 F1587  Sequencing TGCACTTGGACGAACCAGAG alternate primer 
1 F370 Sequencing CCTAACACCAGCCTAACCAG alternate primer 
1 F629 Sequencing TCACATCACCCCATAAACAA alternate primer 
1 F895 Sequencing CACCGCGGTCACACGAT alternate primer 
1 F1095 Sequencing TAGCCCTAAACCTCAACAGT alternate primer 
1 R1309 Sequencing TACTTGCGCTTACTTTGT alternate primer 
1 F1372 Sequencing CTACCCCAGAAAACTACGAT alternate primer 
1 F1594 Sequencing GGACGAACCAGAGTGTAG alternate primer 
1 Sequencing AATGGTTTGGCTAAGGTTGT alternate primer 
1 F1892 Sequencing AAGCTAAGACCCCCGAAACC 
1 R1973 Sequencing CTTCCCACTATTTTGCTACA alternate primer 
1 Sequencing AATTGGTGGCTGCTTTTAGG alternate primer 
1 R965 Sequencing GGGGAGGGGGTGATCTAAAACA alternate primer 
2 F2972 alternate primer 
3 F3635  alternate primer 
R13611 
9 R13935   
9 R14388 Sequencing TTAGCGATGGAGGTAGGATTGG also used for amplification 
F14470 
also used for amplification 
R15774 
also used for amplification 
F16190 
  
R16175 
F1729 
alternate primer 
R2194 
Sequencing ATAGGGTTTACGACCTCGATG 
Sequencing GCCTAGCCGTTTACTCAATCC 
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3 F4183  
3 F4447  alternate primer 
3 R4728  Sequencing TTATGGTTCATTGTCCGGAGAG alternate primer 
4 F4976  Sequencing ATTAAACCAGACCCAGCTACG alternate primer 
4 F5999  Sequencing TCTAAGCCTCCTTATTCGAGC alternate primer 
4 R4983  Sequencing GGTTTAATCCACCTCAACTGCC alternate primer 
4 Sequencing AGGGCTTTGAAGGCTCTTG alternate primer 
4 R6262  GCCTCCACTATAGCAGATGCG alternate primer 
4 F5529 Sequencing alternate primer 
4 R5994 Sequencing TGCCTAGGACTCCAGCTCAT alternate primer 
5 F6744  Sequencing GGCTTCCTAGGGTTTATCGTG alternate primer 
5 F7215  Sequencing CGACGTTACTCGGACTACCC alternate primer 
F7901  Sequencing TGAACCTACGAGTACACCGACTAC alternate primer 
5 R7030  Sequencing TGGGCTACAACGTAGTACGTG alternate primer 
5 R8215  GACGATGGGCATGAAACTG alternate primer 
6 R8669  Sequencing alternate primer 
6 F9449 Sequencing CGGGATAATCCTATTTATTACCTCAG 
7 R9995  Sequencing AGAGTAAGACCCTCATCAATAGATGG alternate primer 
7 F10157 Sequencing ATCCACCCCTTACGAGTGC alternate primer 
7 F10773 Sequencing TCGTCCCAACAATTATATTACTACCA alternate primer 
7 F10704  Sequencing GTCTCAATCTCCAACACATATGG alternate primer 
7 R10524 Sequencing TTCCTAGAAGTGAGATGGTAAATGC alternate primer 
7 R10715 Sequencing CGTAGTCTAGGCCATATGTGTTG alternate primer 
8 Sequencing ACGAACGCACTCACAGTCG alternate primer 
F11901  Sequencing TGCTAGTAACCACGTTCTGGTG alternate primer 
8 R11927 Sequencing TTGATCAGGAGAACGTGGTTAC 
8 R12189  Sequencing AAGCCTCTGTTGTCAGATTCAC alternate primer 
8 F12236 Sequencing GCCCCCATGTCTAACAACAT alternate primer 
8 R12770 Sequencing TCTCAGCCGATGAACAGTTG alternate primer 
F13715 Sequencing GAAGCCTATTCGCAGGATTTC alternate primer 
9 R14118  Sequencing TGGGAAGAAGAAAGAGAGGAAG alternate primer 
10 R14926  Sequencing TGAGGCGTCTGGTGAGTAGTGC alternate primer 
11 F15699 GCCCACTAAGCCAATCACTT alternate primer 
11 R16042 Sequencing CTGCTTCCCCATGAAAGAAC alternate primer 
12 F15971  Sequencing TTAACTCCACCATTAGCACC alternate primer 
12 F16097  Sequencing TACATTACTGCCAGCCACCATG 
12 R16451  Sequencing GCGAGGAGAGTAGCACTCTTG alternate primer 
12 R336  Sequencing TTAAGTGCTGTGGCCAGAAG alternate primer 
12 R419 Sequencing TGCATACCGCCAAAAGATAA alternate primer 
R484 Sequencing TGAGATTAGTAGTATGGGAG alternate primer 
Sequencing TTTCTACCACTCACCCTAGCATTAC alternate primer 
Sequencing TTGGTTATACCCTTCCCGTAC 
R5553  
Sequencing 
ACAGACCAAGAGCCTTCAAA 
5 
Sequencing 
CATTGTTGGGTGGTGATTAGTCG 
alternate primer 
F11760  
8 
alternate primer 
9 
Sequencing 
alternate primer 
12 
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Appendix III. Thermal Cycling conditions and 3100 Run Parameters for ASPE 
 
 
Amplification 
 
Hold   95°C for 5 minutes 
 
3 cycles   95°C for 30 seconds 
  50°C for 55 seconds 
  72°C for 30 seconds  
 
19 cycles 95°C for 30 seconds 
  50°C for 55 seconds* 
  72°C for 30 seconds 
 
9 cycles `  95°C for 30 seconds 
  55°C for 55 seconds 
  72°C for 30 seconds  
 
Hold  72°C for 7 minutes 
 
Hold   4°C for infinity 
 
 
EXO/SAP (post-PCR) 
 
Hold   37°C for 90 minutes 
 
Hold  80°C for 20 minutes 
 
Hold   4°C for infinity 
 
 
Extension (SNaPshot) 
 
Hold   96°C for 10 seconds 
 
25 cycles 96°C for 10 seconds 
  50°C for 5 seconds 
  60°C for 30 seconds 
 
Hold  4°C for infinity  
 
 
SAP (post-extension) 
 
Hold   37°C for 30 minutes 
 
Hold  80°C for 20 minutes 
 
Hold   4°C for infinity  
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3100 Genetic Analyzer Run Parameters 
 
# Parameter Name  Value  
1  Run Temp  60C 
2 Cap Fill Volume  184st 
3 Current Tolerance  100uA 
4 Run Current  100uA 
5 Voltage Tolerance  0.6kV 
6 Pre Run Voltage  15kV 
7 Pre Run Time  60s 
8 Injection Voltage  1kV 
9 Injection Time  13s 
10 Run Voltage  15V 
11 Number Of Steps  10nk 
12 Voultage step Interval 20s 
13 Data Delay Time  200s 
14 Run Time  1200s 
 
 
 
 
Appendix IV: ASPE Amplification and Extension Primer Sequences 
 
 
MP Site Type Primer Name Sequence (5' -> 3') 
Concentration 
(uM) 
A 477 AMP A-477-F(A) CTTTTGGCGGTATGCACTTT 4.55 
A 477 AMP A-477-R(A2) GTTTGGTTGGTTCGGGGTAT 4.55 
A 3010 AMP A-3010-F(A) GCGCAATCCTATTCTAGAGTCC 4.55 
A 3010 AMP A-3010-R(A) TCACGTAGGACTTTAATCGTTGA 4.55 
A 4580 AMP A-4580-F(A) TCTTTGCAGGCACACTCATC 4.55 
A 4580 AMP A-4580-R(A) GCAGCTTCTGTGGAACGAG 4.55 
A 4793 AMP A-4793-F(F2) TGAACCATAACCAATACTACCAATC 4.55 
A 4793 AMP A-4793-R(A) ATGTCAGAGGGGTGCCTTG 4.55 
A 5004 AMP A-5004-F(A) TCCATCATAGCAGGCAGTTG 4.55 
A 5004 AMP A-5004-R(A) TGGTTATGTTAGGGTTGTACGG 4.55 
A 7028 AMP A-7028-F(A) GGCCTGACTGGCATTGTATT 4.55 
A 7028 AMP A-7028-R(A) AAGCCTCCTATGATGGCAAA 4.55 
A 7202 AMP A-7202-F(A) ACGCCAAAATCCATTTCACT 4.55 
A 7202 AMP A-7202-R(A) TTCATGTGGTGTATGCATCG 4.55 
A 10211 AMP A-10211-F(A) ACCACAACTCAACGGCTACA 4.55 
10211 AMP A-10211-R(A2) GGGTAAAAGGAGGGCAATTT 4.55 
A 12858 AMP ATGATACGCCCGAGCAGA 4.55 
A AMP A-12858-R(A) TGTGGGTCTCATGAGTTGGA 4.55 
A 14470 AMP A-14470-F(A) 4.55 
A 14470 AMP A-14470-R(A) GGGGGAGGTTATATGGGTTT 4.55 
A 
A-12858-F(A) 
12858 
CAAGACCTCAACCCCTGACC 
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A 16519 AMP A-16519-F(A) ACCACCATCCTCCGTGAAAT 4.55 
A 16519 AMP A-16519-R(A) AGACCTGTGATCCATCGTGA 4.55 
A 477 SNP 477-F(A) 
TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTC
CCTCCCACTCCCATACTAC 5.00 
A 3010 SNP 3010-F(A) TGTTGGATCAGGACATCCC 1.00 
A 4580 SNP 4580-R(A) 
TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTGGTTAGAA
CTGGAATAAAAGCTAG 7.00 
4793 SNP 4793-R(A) TTTTTCAGAAGTGAAAGGGGGC 15.00 
A 5004 SNP 5004-F(A) TTTTTTTTTTTTTTAAACCCAGCTACGCAAAATC 10.00 
A 7028 SNP 7028-F(A) 
TTTTTTTTTTTTTTTTTTGACACGTACTACGTTGTA
GC 5.00 
A 7202 SNP 7202-F(A) 
TTTTTTTTTTTTTTTTTTTTTTCCACAACACTTTCTC
GGCCT 1.00 
A 10211 SNP 10211-R(A) TTTTTTTTTTACTAAGAAGAATTTTATGGA 15.00 
A 12858 SNP 12858-F(A) 
TTTTTTTTTTTTTTTTTTTTTTTTTTTGCAGCCATTC
AAGCAATCCTATA 10.00 
A 14470 SNP 14470-R(A) 
TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTGG
GAATGATGGTTGTCTTTGG 15.00 
A 16519 SNP 16519-R(A) 
TTTTTTTTTTTTTTTTTTTTTTTTTGTGGGCTATTTA
GGCTTTATG 10.00 
B 477 AMP A-477-F(B) CTTTTGGCGGTATGCACTTT 4.17 
B 477 AMP A-477-R(B2) GTTTGGTTGGTTCGGGGTAT 4.17 
B 3010 A-3010-F(B) GCGCAATCCTATTCTAGAGTCC 4.17 
B 3010 AMP A-3010-R(B) TCACGTAGGACTTTAATCGTTGA 4.17 
B 3915 AMP A-3915-F(B) TTTATCTCCACACTAGCAGAGACC 8.33 
B 3915 AMP  A-3915-R(B2) CTGCGGCGTATTCGATGT 8.33 
B 5004   AMP A-5004-F(B) TCCATCATAGCAGGCAGTTG 4.17 
B 5004 AMP A-5004-R(B) TGGTTATGTTAGGGTTGTACGG 4.17 
B 6776   A-6776-F(B) TGGATACATAGGTATGGTCTGAGC 
B 6776   A-6776-R(B) CGGAGGTGAAATATGCTCGT 4.17 
B 8592   A-8592-F(B) CTGTTCGCTTCATTCATTGC 4.17 
B 8592   A-8592-R(B) TGTTGATGAGATATTTGGAGGTG 4.17 
B 10394   A-10394-F(B2) TCATCCCTCTTATTAATCATCATCC 4.17 
B 10394   A-10394-R(B)) TGAGTCGAAATCATTCGTTTTG 4.17 
B 10754   A-10754-F(B) TGGGCCTAGCCCTACTAGTCT 4.17 
B   TGTGGGTGGTTGTGTTGATT 
11864   A-11864-F(B) AAGGACTTCAAACTCTACTCCCACT 4.17 
4.17 
B 15340   A-15340-F(B) TCACTTCATCTTGCCCTTCA 4.17 
B 15340   A-15340-R(B) 4.17 
B 16519   A-16519-F(B) ACCACCATCCTCCGTGAAAT 4.17 
B 16519   A-16519-R(B2) GTGATCCATCGTGATGTCTT 4.17 
B 477 SNP 477-R (B2) TTTTCGGGGGTTGTATTGATGAGATT 3.80 
B 3010 SNP 3010-F(B) TGTTGGATCAGGACATCCC 0.38 
B 3915   3915-F(B2) 
TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT
TTTTTTTCTTCGACCTTGCCGAAGG 18.98 
B 5004 SNP 5004-F(B) TTTTTTTTTTTTTTAAACCCAGCTACGCAAAATC 18.98 
6776   
6776-F(B) TTTTTTTTTTTTTTTTTGTTTATCGTGTGAGCACAC
CA 3.80 
B 8592   8592-R(B) TTTTTTTTTTTTTTTTTTCAATAGAGGGGGAAATAG 1.90 
A 
AMP 
4.17 
10754 A-10754-R(B2) 4.17 
B 
B 11864   A-11864-R(B) CACAGAGAGTTCTCCCAGTAGG 
TTTTATCGGAATGGGAGGTG 
B 
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AATGAT 
B 10394   
10394-F(B) TTTTTTTTTTTTTTTTTTTTTTTTTTTTAGTGACTACA
AAAAGGATTAGA 18.98 
B 10754   
10754-F(B) TTTTTTTTTTTTTTTTTTTTTTTTTTTCCTAGACTAC
GTACATAACCTAAACCT 7.59 
B 11864   
11864-F(B) TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT
TAGCCTCGCTAACCTCGCC 14.23 
B 15340   15340-R(B2) TTTTTTTTTTTTTCCCGTTTCGTGCAAGAA 9.49 
B 16519   
TTTTTTTTTTTTTTTTTTTTTTTTTGTGGGCTATTTA
GGCTTTATG 1.90 
C 72 AMP A-72-R(C)  TACTGC GAC ATA GGG TGC TC 4.44 
C 72 AMP A-72-F(C)  TCACCCTATTAACCACTCACG 4.44 
C 513 AMP A-513-F(C)  CTTTTGGCGGTATGCACTTT 4.44 
C 513 AMP A-513-R(C)  GTTTGGTTGGTTCGGGGTAT 4.44 
C 4580 AMP A-4580-F(C)  4.44 
C 4580 AMP A-4580-R(C)  GCAGCTTCTGTGGAACGAG 4.44 
C 5250 AMP A-5250-F(C)  AATTCCATCCACCCTCCTCT 7.78 
C 5250 AMP A-5250-R(C)  TGGGGATGATGAGGCTATTG 7.78 
C 11719 AMP A-11719-R(C)  TGAGTGCGTTCGTAGTTTGAG 4.44 
C 11719 AMP A-11719-F(C)  ATCCAAACCCCCTGAAGC 4.44 
C 12438 A-12438-F(C)  CCATCCTTACCACCCTCGTT 4.44 
12438 AMP A-12438-R(C)  TGTTGTGGGGAAGAGACTGA 
C 12810 AMP A-12810-R(C)  CGGTTGTATAGGATTGCTTGAA 4.44 
C AMP A-12810-F(C)  GGCTGAGAGGGCGTAGGA 4.44 
C 14770 AMP A-14793-R(C)  5.56 
C 14770 A-14793-F(C)  CCAATGATATGAAAAACCATCG 5.56 
C 
15833/
15884 AMP A-15833-F(C)  GCTACCCTTTTACCATCATTGG 5.56 
C 
15833/
15884 AMP A-15833-R(C)  CCGGTTTACAAGACTGGTGTATT 5.56 
C 16519 AMP A-16519-R AGACCTGTGATCCATCGTGA 4.44 
C 16519 AMP A-16519-F ACCACCATCCTCCGTGAAAT 4.44 
C 72 72-R(C)  CAATGCTATCGCGTGCA[Y-Q] 3.33 
C 513 SNP 513-F(C)  TTTTTTTTCCCCGCCCATCCTACCCA 0.83 
C 4580 SNP 
TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTGGTTAGAA
CTGGAATAAAAGCTAG 3.33 
C 5250 SNP 5250-F(C)  TTTTTTTTTTTTCCCCCGCTAACCGGCTTT 35.00 
C 11719 SNP 11719-R(C)  TTTTTTTTAGGCAGAATAGTAATGAGGATGTAAG 8.33 
C 12438 SNP 12438-R(C)  
TTTTTTTTTTTTTTTGATGCGACAATGGATTTTACA
TA 3.33 
C 12810 SNP 12810-R(C)  
TTTTTTTTTTTTTTTTTTTTTTTTGGCATCTGCTCGG
GCGTA 
C 14770 SNP 14770-F(C)  13.33 
15833 SNP 15833-F(C)  
TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTCATCCG
TACTATACTTCACAACAATC 8.33 
C 15884 SNP 15884-F(C)  
TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTAA
TTGAAAACAAAATACTCAAATGG 20.00 
C 16519 SNP 16519-R(B) 
TTTTTTTTTTTTTTTTTTTTTTTTTGTGGGCTATTTA
GGCTTTATG 6.67 
D 482 AMP A-482-F(D) CTTTTGGCGGTATGCACTTT 5.00 
16519-R(B) 
TCTTTGCAGGCACACTCATC 
AMP 
C 4.44 
12810 
GCCGAAGTTTCATCATGC 
AMP 
SNP 
4580-R(C)  
5.00 
TTTTTTTTTTTTTTTTTTTTTTTTTTTTTGACCCCAAT
ACGCAAAACTAA 
C 
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D 482 AMP A-482-R(D) GTTTGGTTGGTTCGGGGTAT 5.00 
D 5198 AMP A-5198-F(D) CCACGACCCTACTACTATCTCG 5.00 
D 5198 AMP A-5198-R(D) GGGCAAAAAGCCGGTTAG 5.00 
D 6260 AMP A-6260-R(D) GGTGGGAGTAGTTCCCTGCT 5.00 
D AMP A-6260-F(D) TTTCCCCGCATAAACAACAT 5.00 
D 9548 AMP A-9548-F(D) TTTCTGAGCCTTTTACCACTCC 5.00 
D 9548 AMP A-9548-R(D) GAGTGGGACTTCTAGGGGGATTT 5.00 
D 9635 AMP A-9635-R(D) TTGAATTATTTGGTTTCGGTTG 5.00 
D 9635 AMP A-9635-F(D2) CCGTATTACTCGCATCAGGA 5.00 
D 11485 AMP A-11485-R(D) CGTAGGCAGATGGAGCTTGT 5.00 
D 11485 AMP A-11485-F(D) 5.00 
D 11914 AMP A-11914-F(D) CTCGCTAACCTCGCCTTACC 5.00 
D 11914 AMP A-11914-R(D) TGTGACTAGTATGTTGAGTCCTGTAA 5.00 
D 15355 AMP A-15355-F(D) TCACTTCATCTTGCCCTTCA 5.00 
D 15355 AMP A-15355-R(D) TTTTATCGGAATGGGAGGTG 5.00 
D 15884 AMP A-15833-R(C) CCGGTTTACAAGACTGGTGTATT 
D 15884 AMP A-15833-F(C) GCTACCCTTTTACCATCATTGG 5.00 
AMP A-16368-R(D) 
16368 AMP A-16368-F(D) CATAGTACATAAAGCCATTTACCG 5.00 
D 482 SNP In Progress   
D 5198 SNP 
mtSNP5198-
R(short) AGAGGAGGGTGGATGGAAT   
D 6260 SNP 6260-R(D) TTTTTTTTACCTGTTCCTGCTCCGGC   
D 9548 SNP   In Progress   
D 9635 SNP mtSNP9635-F TTTTTTTTTTTTTCTCGCATCAGGAGTATC   
D 11485 SNP   In Progress   
D 11914 SNP   In Progress   
D 15355 SNP 15355-R(D) TTTTTTTTTTTTTTCCTAGGGGGTTGTTTGATCC   
D 15884 SNP 15884-F(CD) 
TTTTTTTTTTTTTAATTGAAAACAAAATACTCAAATG
G   
D 16368 SNP 16368-R(D) 
TTTTTTTTTTTTTTTTTTTTTTCTATCTGAGGGGGGT
CATCC   
E 4808 AMP A-4808-R(E) AAGAAGCAGGCCGGATGT 6.00 
E 4808 AMP A-4808-F(E) CCAATACTACCAATCAATACTCATCA 6.00 
E 5147 AMP A-5147-R(E) AATTAAGGGTGTTAGTCATGTTAGC 6.00 
E 5147 A-5147-F(E) CCGTACAACCCTAACATAACCA 6.00 
E 9380 AMP A-9380-F(E) CATAACGCTCCTCATACTAGGC 
E 9380 AMP A-9380-R(E) GGACAGGTGGTGTGTGGTG 6.00 
E 9899 AMP A-9899-F(E) TTTCCTCACTATCTGCTTCATCC 6.00 
E 9899 AMP A-9899-R(E) TCAAACCACATCTACAAAATGC 
E 11914 AMP A-11914-F(E2) 14.00 
E 11914 AMP TAGAGGGAGTATAGGGCTGTGC 14.00 
E 15067 A-15067-F(E) TTCTTTATCTGCCTCTTCCTACA 6.00 
E 15067 A-15067-R(E) TGCTATAGTTGCAAGCAGGAG 6.00 
16519 AMP A-16519-F ACCACCATCCTCCGTGAAAT 6.00 
E 16519 AMP A-16519-R AGACCTGTGATCCATCGTGA 6.00 
E SNP 4808-F(E) GGAATAGCCCCCTTTCACTT 20.00 
E 5147 SNP 5147-F(E2) 
TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTCAA
CTTAAACTCCAGCACCAC 6.67 
6260 
CGCTGGGTCAATAGTACTTGC 
5.00 
D 16368 ATTTCACGGAGGATGGTGGT 5.00 
D 
  
AMP 
6.00 
6.00 
AGCAAGCCTCGCTAACCTC 
A-11914-R(E2) 
AMP 
AMP 
E 
4808 
111 
This document is a research report submitted to the U.S. Department of Justice. This report has not 
been published by the Department. Opinions or points of view expressed are those of the author(s) 
and do not necessarily reflect the official position or policies of the U.S. Department of Justice.
E 9380 9380-F(E) TTTTCAACACACTAACCATATACCAATGATG 1.67 
E 9899 SNP 9899-F(E) TTTTTTTTTACTAATATTTCACTTTACATCCAAACA 20.00 
E 11914 SNP 
TTTTTTTTTTTTTTTTTTTTTTTTTGGAGAGTGATAT
TTGATCAGGAGAA 33.33 
E 15067 SNP 15067-F(E) 
TTTTTTTTTTTTTTTTTTCGAGGCCTATATTACGGA
TCATT 6.67 
E 16519 SNP 16519-R(B) 
TTTTTTTTTTTTTTTTTTTTTTTTTGTGGGCTATTTA
GGCTTTATG 10.00 
F 64 AMP A-64-R(F) TACTGCGACATAGGGTGCTC 5.56 
64 AMP A-64-F(F) ACATCACGATGGATCACAGG 5.56 
F 4745 AMP CTGGGACTCAGAAGTGAAAGG 3.33 
F AMP A-4745-F(F) TCCTTCTAATAGCTATCCTCTTCAA 3.33 
F 10211 AMP A-10211-F(F) 6.67 
F 10211 A-10211-R(F2) GGGTAAAAGGAGGGCAATTT 6.67 
10394 AMP A-10394-F(F) CCATGAGCCCTACAAACAACT 
F 10394 AMP TGAGTCGAAATCATTCGTTTTG 6.67 
F TGGGACGATTAGTTTTAGCATTG 5.56 
AMP A-10685-F(F2) CCCACTCCCTCTTAGCCAAT 5.56 
GGCTTCGACATGGGCTTT 
F 11377 A-11377-F(F3) ACTCACTCTCACTGCCCAAGA 3.33 
14470 AMP A-14470-R(F) GGGGGAGGTTATATGGGTTT 6.67 
F 14470 AMP A-14470-F(F) CAAGACCTCAACCCCTGACC 6.67 
F 14560 AMP A-14560-F(F) CAACCATCATTCCCCCTAAA 5.56 
F 14560 AMP A-14560-R(F3) TTGTGGGGTTTTCTTCTAAGC 5.56 
F 14869 AMP A-14869-R(F) AGGCGTCTGGTGAGTAGTGC 1.11 
F 14869 AMP A-14869-F(F) CACCCCATCCAACATCTCC 1.11 
F 16390 AMP A-16390-F(F) GCACATTACAGTCAAATCCCTTC 5.56 
F 16390 AMP A-16390-R(F) TAGCACTCTTGTGCGGGATA 5.56 
F 64 SNP 64-F(F4) 
TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT
CCATGCATTTGGTATTTTCGT 6.00 
F 4745 4745-F(F) GAACCATAACCAATACTACCAATCA 2.00 
F 10211 SNP 10211-R(F) 
TTTTTTTTTTTTTTTTTTACTAAGAAGAATTTTATGG
A 22.00 
F 10394 SNP 10394-F(F) TTTTTTTTTTTTAGTGACTACAAAAAGGATTAGA 30.00 
F 10685 SNP 10685-R(F2) TTTTTTTTTTACTAGTAGGGCTAGGCCCAC 6.00 
F 11377 SNP 11377-R 
TTTTTTTTTTTTTTTTTTTTAGTGGAGTCCGTAAAG
AGGTAT 2.00 
F 14470 14470-F(F) 
TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTGGGAA
TGATGGTTGTCTTTGG 22.00 
F 14560 SNP 14560-F(F) 
TTTTTTTTTTTTTTTTTTTTTTCCAAAATTCAGAATA
ATAACACACCC 2.00 
F 14869 SNP 14869-F(F) ACTCCTTGGCGCCTGCCT 0.66 
F 16390 SNP 16390-R 
TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTGAGGATG
GTGGTCAAGGGAC 6.00 
G 
3826, 
3834 AMP A-3826-F(G) 6.67 
G 
3826, 
3834 AMP TTGGTCTCTGCTAGTGTGGAGA 6.67 
G 4688 A-4688-F (G) CAAGTATTTCCTCACGCAAGC 6.67 
G 4688 AMP A-4688-R (G) TTGATTGGTAGTATTGGTTATGGTT 6.67 
6293 AMP A-6293-F(G) 
SNP 
11914-R(E3) 
F 
A-4745-R(F) 
4745 
ACCACAACTCAACGGCTACA 
AMP 
F 6.67 
A-10394-R(F) 
10685 AMP A-10685-R(F2) 
F 10685 
F 11377 AMP A-11377-R(F2) 3.33 
AMP 
F 
SNP 
SNP 
TCCTTTAACCTCTCCACCCTTA 
A-3826-R(G) 
AMP 
G TCCTACTCCTGCTCGCATCT 3.33 
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G 6293 A-6293-R(G) GGTGTAAGGAGAAGATGGTTAGG 
7891 AMP A-7891-R(G) 3.33 
G 11533 AMP A-11533-F(G) CGCTGGGTCAATAGTACTTGC 3.33 
G 11533 AMP A-11533-R(G) CGTAGGCAGATGGAGCTTGT 3.33 
G 12007 AMP A-12007-F(G) CAGGACTCAACATACTAGTCACAGC 3.33 
G 12007 AMP A-12007-R(G) TTCTCGTGTGAATGAGGGTTT 3.33 
G 12795 AMP A-12795-F(G) CCAACTGTTCATCGGCTGAG 3.33 
G 12795 AMP A-12795-R(G) CTTGAATGGCTGCTGTGTTG 3.33 
G 15043 AMP A-15043-F(G) CGCTACCTTCACGCCAAT 6.67 
G 15043 AMP A-15043-R(G) ATGCCGATGTTTCAGGTTTC 6.67 
G 16390 AMP A-16390-R(G) TAGCACTCTTGTGCGGGATA 6.67 
G 16390 AMP A-16390-F(G2) ACCGTACATAGCACATTACAGTCAA 6.67 
G 16519 AMP A-16519-F(G2) CCATAACACTTGGGGGTAGC 6.67 
G 16519 AMP A-16519-R(G2) 6.67 
G 3826 3826-F(G) TTTTCACAACACAAGAACACCTCTGA 5.00 
G 3834 SNP 3834-R(G) GGCCAAGGGTCATGATGG 
G 4688 SNP 4688-F(G2) 
TTTTTTTTTTTTTTTTTTTTCGCATCCATAATCCTTC
TAATAGC 5.00 
G 6293 SNP 6293-F(G2) TTTTTTGGAACAGGTTGAACAGTCTACCC 10.00 
G 7891 SNP 7891-R(G2) TTTTTTTTTGTACTCGTAGGTTCAGTACCATTG 2.50 
G 11533 SNP 11533-R(G2) 
TTTTTTTTTTTTTTTTTTGGGATAGTACAAGGAAGG
GGTA 2.50 
G 12007 SNP 12007-F(G) 
TTTTTTTTTTTCCTCTACATATTTACCACAACACAA
TG 2.50 
G 12795 SNP 12795-F(G2) 
TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTGGCGT
AGGAATTATATCCTTCTT 2.50 
G 15043 SNP 15043-F(G2) 
TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT
TGCCTCTTCCTACACATCGG 10.00 
G 16390 SNP 16390-R(G2) 
TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTGAGGATG
GTGGTCAAGGGAC 10.00 
G 165119 SNP 16519-F(G) 
TTTTTTTTTTTTTTTTTTTTTTTTACATCTGGTTCCT
ACTTCAGGG 10.00 
H 4688 AMP A-4688-F (H) CAAGTATTTCCTCACGCAAGC 2.00 
H 4688 AMP A-4688-R (H) TTGATTGGTAGTATTGGTTATGGTT 2.00 
H 11377 AMP A-11377-F(H2) CAAACTCCTGAGCCAACAACT 2.00 
H 11377 AMP A-11377-R(H2) GGCTTCGACATGGGCTTT 2.00 
H 12795 AMP A-12795-F(H) CCAACTGTTCATCGGCTGAG 2.00 
H 12795 AMP A-12795-R(H) CTTGAATGGCTGCTGTGTTG 2.00 
H 13293 AMP A-13293-F(H) CGTAGCCTTCTCCACTTCAA 2.00 
H 13293 AMP A-13293-R(H) CTTTGAAGAAGGCGTGGGTA 2.00 
H 14305 AMP A-14305-F(H) CCAATAGGATCCTCCCGAAT 2.00 
H 14305 AMP A-14305-R(H) AAAGAGTATGATGGGGTGGTG 2.00 
H 16519 AMP A-16519-F(H) ACCACCATCCTCCGTGAAAT 2.00 
H 16519 AMP A-16519-R(H) AGACCTGTGATCCATCGTGA 2.00 
H 4688 SNP 4688-F(H) TTTTTTTTCGCATCCATAATCCTTCTAATAGC 10.00 
H 11377 SNP 11377-R(H) 
TTTTTTTTTTTTTTTTTTTTAGTGGAGTCCGTAAAG
AGGTAT 
H 12795 SNP 12795-F(H) 
TTTTTTTTTTTTTTTGGCGTAGGAATTATATCCTTC
TT 5.00 
AMP 3.33 
G 7891 AMP A-7891-F(G) CATAACAGACGAGGTCAACGA 3.33 
G TGGGGGAAGTATGTAGGAGTTG 
AGAGCTCCCGTGAGTGGTTA 
SNP 
5.00 
10.00 
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H 13293 SNP GAATGCTAGGTGTGGTTGGTT 1.00 
H 14305 SNP 14305-R(H) TGTGGTAAACTTTAATAGTGTAGGAAG 5.00 
H 16519 SNP 16519-F(H2) 
TTTTTTTTTTTTTTTTTTTTTTTTTACATCTGGTTCCT
ACTTCAGGG 10.00 
13293-R(H) 
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